Archive for January, 2020

News

Independence Health Group CEO and Chamber of Commerce chairman Dan Hilferty shares his forecast for the growth of the region's bustling health care ecosystem.

Dan Hilferty is the chairman of the Chamber of Commerce for Greater Philadelphia and the CEO of Independence Health Group.

Its been one year since the Chamber of Commerce for Greater Philadelphia, through its CEO Council for Growth and with its partners and collaborators, formally launched the Cell & Gene Therapy and Connected Health Initiative to leverage our regions assets and existing strengths.

My predictions for the initiative and the industry for the coming year are:

Groundbreaking discoveries with origins here have resulted in six FDA-approved therapies since 2017. In 2020, our outstanding research institutions will continue to build on the history of discovery and the recent successes here, leading to more breakthroughs to benefit patients and improve and save lives.

Increased awareness of Greater Philadelphia as a center of innovative excellence in R&D, health care and life sciences will continue to result in an increase in the number of companies locating here as they seek to build out where there is talent, lab space, and research partnership opportunities all close by.

The Chambers Select Greater Philadelphia Council will continue to be a key leader in marketing the region nationally and globally and serving as a connector to welcome these businesses and leaders, and the Chambers CEO Council for Growth is working in 2020 to assess infrastructure needs and identifying opportunities to support this R&D and cell and gene therapy focused growth.

The Greater Philadelphia metro area ranked in the top 10 most active regions in the U.S. for venture funding last year, with venture capital funding in health care more than doubling over the past four years. Recent acquisitions and funding wins speak to the momentum, and we can certainly expect investment growth to continue in 2020.

The region is home to nearly 100 colleges and universities. Through efforts such as the Chambers Regional College and University Presidents Alliance, comprised of higher education leaders focusing on opportunities for collaboration and advocacy, attracting talent to these institutions and retaining talent in our region will continue. The regions robust and growing ecosystem of laboratories, start-ups, manufacturing, and health care technology companies will create more job opportunities which will drive even higher graduate retention.

Connected health technology, through innovative partnerships like our work with Comcast on Quil, is another area in which our region is creating breakthroughs, as technology gives patients new tools and experiences to manage their care. We can expect new developments in this quick-moving industry.

Daniel J. Hilferty is chairman of the Chamber of Commerce for Greater Philadelphia chief executive officer of Independence Health Group, parent of Independence Blue Cross.

Excerpt from:
5 Predictions for Philadelphia's Cell and Gene Therapy Sector in 2020 - Philadelphia magazine

Teens with obesity and polycystic ovary syndrome (PCOS) have more unhealthy gut bacteria, suggesting the microbiome may play a role in the disorder, according to new research published in the Endocrine Societys Journal of Clinical Endocrinology & Metabolism.PCOS is complicated endocrine disorder affecting 6 percent to 18 percent of women of reproductive age and work in adult women indicates that changes in bacteria be involved. The hormone disorder is characterized by elevated testosterone levels in the blood that cause acne, excess hair growth and irregular periods. Teens with PCOS often also struggle with obesity and have a higher risk for type 2 diabetes, infertility, and depression.

We found that in adolescents with PCOS and obesity, the bacterial profile (microbiome) from stool has more unhealthy bacteria compared to teens without PCOS, said the studys corresponding author, Melanie Cree Green, M.D., Ph.D., of Childrens Hospital Colorado in Aurora, Colo. The unhealthy bacteria related to higher testosterone concentrations and markers of metabolic complications.

The researchers studied 58 teens with obesity and found that girls with PCOS have an altered gut microbiome compared to those without the condition. These girls had more unhealthy bacteria in their stool which was related to higher testosterone levels and other markers of metabolic syndrome, such as higher blood pressure, liver inflammation and plasma triglycerides.

The gut microbiome may play a role in PCOS and its related metabolic complications, and these changes can be found in teenagers who are early in the course of the condition, Green said.ReferenceJobira et al. (2020) Obese adolescents with PCOS have altered biodiversity and relative abundance in gastrointestinal microbiota. Journal of Clinical Endocrinology & Metabolism. DOI: https://doi.org/10.1210/clinem/dgz263

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the article here:
"Unhealthy" Gut Microbiome Linked to PCOS and Obesity in Teens - Technology Networks

The first symposium of the South West Brain Tumour Centre was held on Thursday at Derriford Hospital in Plymouth. During a fascinating and very well attended event, topics covered included the mechanism of tumour development, new drug targets, new biomarkers and brain tumour imaging. The South West Brain Tumour centre is of course one of the UK Centres of Excellence funded by Brain Tumour Research.

A really big cancer wide story this week is here Immune discovery 'may treat all cancer' applicable to some solid tumours but not yet brain it really shows the direction of travel toward immunotherapy I have recommended this book before but if interested please do read The Breakthrough by Charles Graeber it is available on Amazon and you can read reviews here - http://www.charlesgraeber.com.Researchers uncover novel drug target for glioblastoma by revealing a cellular pathway that appears to contribute to glioma stem cell spread and proliferation. This pathway shows that glioma stem cells ability to access key nutrients in their surrounding microenvironment is integral for their maintenance and spread. Finding a way to interrupt this feedback loop will be important for treating glioblastoma.

An intelligent molecule could significantly extend the lives of patients with glioblastoma, research finds. The molecule, called ZR2002, which can be administered orally and is capable of penetrating the blood-brain barrier, could delay the multiplication of glioblastoma stem cells resistant to standard treatment. According to scientists in the Metabolic Disorders and Complications Program at the Research Institute of the McGill University Health Centre (RI-MUHC) the ZR2002 molecule is designed to kill two birds with one stone: on top of attacking the tumour, it destroys its defence system.

Researchers find clues to drug resistance in medulloblastoma subtype.US scientists have identified specific types of cells that cause targeted treatment to fail in a subtype of medulloblastoma. They found while the majority of cells responded to treatment, diverse populations within the tumour continue to grow leadingto treatment resistance. They concluded that the diversity of cells within tumours allow them to become rapidly resistant to precisely targeted treatments," and that due to this tumour cell diversity, molecularly precise therapies should be used in combinations to be effective."

Nanoparticles deliver 'suicide gene' therapy to paediatric brain tumours growing in mice So-called "suicide genes" have been studied and used in cancer treatments for more than 25 years. Researchers report here that a type of biodegradable, lab-engineered nanoparticle they fashioned can successfully deliver a ''suicide gene'' to paediatric brain tumour cells implanted in the brains of mice.

According to a study that uncovers an unexpected connection between gliomas and neurodegenerative diseases a protein typically associated with neurodegenerative diseases like Alzheimers might help scientists explore how gliomas become so aggressive. The new study, in mouse models and human brain tumour tissues, was published in Science Translational Medicine and found a significant expression of the protein TAU in glioma cells, especially in those patients with better prognoses. Patients with glioma are given a better prognosis when their tumour expresses a mutation in a gene called isocitrate dehydrogenase 1 (IDH1). In this international collaborative study led by the Instituto de Salud Carlos III-UFIEC in Madrid, Spain, those IDHI mutations stimulated the expression of TAU. Then, the presence of TAU acted as a brake for the formation of new blood vessels, which are necessary for the aggressive behaviour of the tumours.

'Innovative research award' helps Colorado scientists block brain cancer escape routes Cancers used to be defined by where they grow in the body - lung cancer, skin cancer, brain cancer, etc. But work in recent decades has shown that cancers sharing specific genetic changes may have more in common than cancers that happen to grow in an area of the body. For example, lung cancers, skin cancers, and brain cancers may all be caused by mutation in a gene called BRAF. Drugs targeting BRAF have changed the treatment landscape for melanoma, an aggressive form of skin cancer, and are also in use against lung cancers and brain cancers with BRAF mutations. It is really worth clicking through to read more on this and the ultimate goal of identifying new potential targets for combination therapy and new agents that could be added to BRAF inhibiting drugs in brain cancer to keep the cancer from developing resistance.

Related reading:

If you found this story interesting or helpful,sign up to our weekly e-newsand keep up to date with all the latest from Brain Tumour Research.

Go here to read the rest:
Weekly pick of brain tumour research news from around the world - Brain Tumour Research

The global market for Cancer Therapies is projected to reach US$220. 5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease.

New York, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Cancer Therapies Industry" - https://www.reportlinker.com/p05817674/?utm_source=GNW Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities. - Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancers diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancers mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing. Aberrations in alternative splicing are linked to cancers progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancers biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide. - Competitors identified in this market include, among others, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company , F. Hoffmann-La Roche Ltd., Glaxosmithkline Plc, Johnson & Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc.,Takeda Pharmaceutical Company Limited.

Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

CANCER THERAPIES MCP-1MARKET ANALYSIS, TRENDS, AND FORECASTS, JANUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Cancer Therapies: An Outlook Chemotherapy & Targeted Therapy Lead the Global Cancer Therapies Market By Cancer Type USA Leads the Cancer Therapies Market Biotherapies to Drive Growth Rise in Cancer Incidence & Access to Modern Therapeutics Foster Growth Total Number of New Cancer Cases by Type: 2018 Total Number of Cancer Deaths by Type: 2018 Cancer Incidence by Region: 2018 Cancer Mortality by Region: 2018 Age-Standardized Incidence and Mortality Rates of All Cancers (per 100000 Population) by Region: 2018 Cancer Research Spending Continues to Witness Growth Number of FDA-Approved Cancer Drugs: 2010-2018 Select Cancer Drug Approvals in 2019 Select Cancer Drug Approvals in 2018 Cancer Drug Pipeline to Change the Pharma Landscape Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019 Global Competitor Market Shares Cancer Therapies Competitor Market Share Scenario Worldwide (in %): 2019 Select Leading Cancer Drugs Worldwide by Sales: 2018

2. FOCUS ON SELECT PLAYERS AbbVie, Inc. (USA) Amgen, Inc. (USA) Astellas Pharma, Inc. (Japan) AstraZeneca Plc. (UK) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Select Late Stage Compounds in Bristol-Myers Squibb Companys Oncology Pipeline (As of 2019) Celgene Corporation (USA) Eli Lilly and Company (USA) F. Hoffmann-La Roche Ltd. (Switzerland) Glaxosmithkline Plc (UK) Johnson & Johnson Services, Inc. (USA) Merck KGaA (Germany) Novartis AG (Switzerland) Pfizer, Inc. (USA) Takeda Pharmaceutical Company Limited (Japan)

3. MARKET TRENDS & DRIVERS Industry Focuses on New Approaches to Treat Cancer Recent Advancements in Cancer Drug Discovery A New Immunotherapy Technique that Improves Efficacy and Safety of Cancer Treatment Developed by an Institute for Molecular Engineering Research Team Lymphoma Therapy Developed by BeiGene Secures US FDA Approval New Linker Technology for Enhancing Stability of ADCs Personalized Medicine Gains Importance Companion Diagnostics Accelerate Role of Personalized Medicine in Cancer Care North American Companion Diagnostics Market (2019) European Companion Diagnostics Market by Disease Area (2019) Innovations in Cancer Drug Delivery: Key Factor in Product Differentiation Peptoid-based Nanotubes Allow Precise, Targeted Delivery of Cancer Drugs Combination Therapy: A Double Whammy Success Patent Expiries of Branded Drugs to Trigger Generic Competition Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe Gene Therapy based Approaches Present Potential Weapon for Battle against Cancer Development of Novel Drug Candidates and Potential Therapies Non-Viral Gene Therapy to Expedite Cancer Research and Introduction of New Therapies Rise in Patient Assistance Programs (PAPs) Top Financial Concerns for Cancer Patients: Ranked In Order of Influence Oral Oncolytic Abandonment Rate (in %) by Patient Out-of-Pocket Expenses Growth Drivers and Restraints Demographics & Lifestyles Raise the Risk of Cancer Percentage Breakdown of New Cases for All Cancers by Gender (2019) Percentage Breakdown of New Cases for Colon and Rectum Cancers by Gender (2019) Percentage Breakdown of New Cases for Lung & Bronchus Cancers by Gender (2019) Unmet Needs Leave Scope for Further Research and Development Low Entry Barriers in Cancer Research Encourages Breakthrough Developments Increasing Investments by National Health Authorities NCI Funding for Cancer Research (2002, 2008, 2014 and 2020) Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth Molecular Imaging of Cancer: Critical in Improving Patient Outcomes Innovations, Improvements, and Approvals Propel Growth Select Cancer Drug Approvals (2018 & 2019) Emerging Challenges in Cancer Drug Development Drug Failures Deter Prospects of New Therapies High Prices of Targeted Therapies Act as a Speed Breaker Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2016 Cancer Drug Approval Processes Need to Become More Flexible for Encouraging Innovation Limited Tumor Specificity and Toxicity Complicated Treatment Protocols: A Major Stumbling Block in Patient Compliance Reduced Smoking Global Cigarette Consumption Per Capita by Select Countries for 1970 and 2018 Reimbursement Coverage Remains a Major Challenge Increase in Multidrug Resistance Stringent Regulations Delay Market Approval Challenges Encountered in Clinical Trials Overview of Cancer Therapy Segments Immunotherapy: A Promising Segment Global Cancer Immunotherapy Market by Therapy Type (in %) for 2019 Monoclonal Antibodies for Cancer Treatment Monoclonal Antibodies in Late-Stage Clinical Trials for Cancer Treatment Vaccines: A Promising Future Area of Cancer Therapeutics Approved Therapeutic Cancer Vaccines Worldwide CAR-T Therapy: An Innovative Therapy Focused on Engineering of Patients Immune Cells for Cancer Treatment UK Researchers New Approach Holds Potential to Boost Immunotherapies Targeted Therapy: An Overview Types of Targeted Therapy Chemotherapy: An Overview Types of Chemotherapy Risks Associated with Chemotherapy Hormone Therapy Drug Classes in Hormone Therapy Cancer Types, Approved and Pipeline Drugs Prostate Cancer Global Sales of Leading Prostate Cancer Drugs in US$ Million: 2018 Select General Risk Factors and their Relative Risk Rate in Prostate Cancer Select FDA Approved Drugs for Palliative Treatment of Advanced Prostate Cancer Select Drugs that Received Approval for Castration-Resistant Prostate Cancer (CRPC) Prostate Cancer Phase IV Completed Clinical Trials with Results Lung Cancer Age-Standardized Lung Cancer Rates for Select Countries Age-Standardized Lung Cancer Rates in Men for Select Countries Age-Standardized Lung Cancer Rates in Women for Select Countries Select FDA-Approved Non-Small Cell Lung Cancer Drugs Select Phase IV Completed Clinical Trials with Results: As of Dec, 2019 Select Phase III Completed Clinical Trials with Results: As of December 30, 2019 Breast Cancer Select FDA Approved Breast Cancer Drugs Breast Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Breast Cancer Select Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Renal Cancer Select FDA-Approved Renal Cell Carcinoma Drugs Cervical Cancer Colorectal Cancer Select FDA-Approved Colorectal Cancer Drugs Skin Cancer Skin Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Pancreatic Cancer Non-Hodgkins Lymphoma Leukemia Standard Approved Mode of Therapy for AML by Age Group Blood Cancer Phase IV Completed Clinical Trials with Results: As of Dec 30, 2019 Blood Cancer Phase III Completed Clinical Trials with Results: As of Dec 30, 2019 Bladder Cancer Endometrial Cancer

4. GLOBAL MARKET PERSPECTIVE Table 1: Cancer Therapies Global Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 2: Cancer Therapies Global Retrospective Market Scenario in US$ Million by Region/Country: 2009-2017 Table 3: Cancer Therapies Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Chemotherapy (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 5: Chemotherapy (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 6: Chemotherapy (Treatment Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Targeted Therapy (Treatment Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 8: Targeted Therapy (Treatment Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 9: Targeted Therapy (Treatment Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Immunotherapy (Treatment Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 11: Immunotherapy (Treatment Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 12: Immunotherapy (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 13: Hormonal Therapy (Treatment Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2to 2025 Table 14: Hormonal Therapy (Treatment Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 15: Hormonal Therapy (Treatment Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 16: Other Treatment Types (Treatment Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 17: Other Treatment Types (Treatment Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 18: Other Treatment Types (Treatment Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 19: Blood Cancer (Cancer Type) World Market Estimates and Forecasts in US$ Million by Region/Country: 2018 to 2025 Table 20: Blood Cancer (Cancer Type) Market Worldwide Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 21: Blood Cancer (Cancer Type) Market Percentage Share Distribution by Region/Country: 2009 VS 2019 VS 2025 Table 22: Breast Cancer (Cancer Type) Market Opportunity Analysis Worldwide in US$ Million by Region/Country: 2018 to 2025 Table 23: Breast Cancer (Cancer Type) Global Historic Demand in US$ Million by Region/Country: 2009 to 2017 Table 24: Breast Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 25: Prostate Cancer (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 26: Prostate Cancer (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 27: Prostate Cancer (Cancer Type) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 28: Gastrointestinal Cancer (Cancer Type) Potential Growth Markets Worldwide in US$ Million: 2018 to 2025 Table 29: Gastrointestinal Cancer (Cancer Type) Historic Market Perspective by Region/Country in US$ Million: 2009 to 2017 Table 30: Gastrointestinal Cancer (Cancer Type) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 31: Gynecologic Cancer (Cancer Type) Geographic Market Spread Worldwide in US$ Million: 2018 to 2025 Table 32: Gynecologic Cancer (Cancer Type) Region Wise Breakdown of Global Historic Demand in US$ Million: 2009 to 2017 Table 33: Gynecologic Cancer (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025 Table 34: Lung Cancer (Cancer Type) World Market Estimates and Forecasts by Region/Country in US$ Million: 2018 to 2025 Table 35: Lung Cancer (Cancer Type) Market Historic Review by Region/Country in US$ Million: 2009 to 2017 Table 36: Lung Cancer (Cancer Type) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 37: Other Cancer Types (Cancer Type) World Market by Region/Country in US$ Million: 2018 to 2025 Table 38: Other Cancer Types (Cancer Type) Historic Market Analysis by Region/Country in US$ Million: 2009 to 2017 Table 39: Other Cancer Types (Cancer Type) Market Share Distribution in Percentage by Region/Country: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Market Overview Rising Cancer Cases Spur Growth in Anti-Cancer Drugs Market Estimated Number of New Cancer Cases and Deaths in the US (2019) Number of Cancer Drugs in Development for the Years 2006, 2009, 2012, 2015 and 2018 Patient Assistance Programs Alleviate Cost Burden of Patients to Some Extent Personalized Medicine Gathers Momentum for Cancer Treatment in the US A Surging US Prostate Cancer Therapeutics Market Medicaid Reimbursement Rates for Cancer Treatment with Radiation Indicate Notable Disparity among States Oncology Care Model to Improve Quality and Reduce Financial Toxicity of Cancer Care CMS Hikes Reimbursement Rate for CAR-T Therapy Market Analytics Table 40: United States Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 41: Cancer Therapies Market in the United States by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 42: United States Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 43: United States Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 44: Cancer Therapies Market in the United States by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 45: United States Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 CANADA Number of New Cancer Cases in Canada: 2019 Market Analytics Table 46: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 47: Canadian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 48: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 49: Canadian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 50: Canadian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 51: Cancer Therapies Market in Canada: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 JAPAN Table 52: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 53: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 54: Japanese Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 55: Japanese Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 56: Cancer Therapies Market in Japan: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 57: Japanese Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 CHINA Cancer Therapies Market: Overview Number of New Cancer Cases Diagnosed (in Thousands) in China: 2018 Chinese Drug Makers Look to Strengthen Domestic Presence with Low-cost Products Market Analytics Table 58: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 59: Cancer Therapies Historic Market Analysis in China in US$ Million by Treatment Type: 2009-2017 Table 60: Chinese Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 61: Chinese Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 62: Cancer Therapies Historic Market Analysis in China in US$ Million by Cancer Type: 2009-2017 Table 63: Chinese Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 EUROPE Rising Cancer Incidence and New Drug Development Augur Well for European Cancer Therapies Market Cancer Incidence in Europe: Number of New Cancer Cases (in Thousands) by Site for 2018 Number of New Cancer Cases Diagnosed (in Thousands) in the UK: 2018 Market Analytics Table 64: European Cancer Therapies Market Demand Scenario in US$ Million by Region/Country: 2018-2025 Table 65: Cancer Therapies Market in Europe: A Historic Market Perspective in US$ Million by Region/Country for the Period 2009-2017 Table 66: European Cancer Therapies Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 68: Cancer Therapies Market in Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 69: European Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 70: European Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 71: Cancer Therapies Market in Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 72: European Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 FRANCE Table 73: Cancer Therapies Market in France by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 74: French Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 75: French Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 76: Cancer Therapies Market in France by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 77: French Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 78: French Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 GERMANY Table 79: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 80: German Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 81: German Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 82: Cancer Therapies Market in Germany: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 83: German Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 84: German Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ITALY Table 85: Italian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 86: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Treatment Type: 2009-2017 Table 87: Italian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 88: Italian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 89: Cancer Therapies Historic Market Analysis in Italy in US$ Million by Cancer Type: 2009-2017 Table 90: Italian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED KINGDOM Table 91: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 92: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 93: United Kingdom Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 94: United Kingdom Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 95: Cancer Therapies Market in the United Kingdom: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 96: United Kingdom Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 SPAIN Table 97: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 98: Spanish Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 99: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 100: Spanish Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 101: Spanish Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 102: Cancer Therapies Market in Spain: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 RUSSIA Table 103: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 104: Cancer Therapies Market in Russia by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 105: Russian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 106: Russian Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 107: Cancer Therapies Market in Russia by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 108: Russian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF EUROPE Table 109: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 110: Cancer Therapies Market in Rest of Europe in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 111: Rest of Europe Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 112: Rest of Europe Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 113: Cancer Therapies Market in Rest of Europe in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 114: Rest of Europe Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 ASIA-PACIFIC An Insight into Asia-Pacific Market for Cancer Therapies Cancer Incidence in Asia: Number of New Cancer Cases (in Thousands) for 2019 Market Analytics Table 115: Asia-Pacific Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 116: Cancer Therapies Market in Asia-Pacific: Historic Market Analysis in US$ Million by Region/Country for the Period 2009-2017 Table 117: Asia-Pacific Cancer Therapies Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 118: Cancer Therapies Market in Asia-Pacific by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 119: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 120: Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 121: Cancer Therapies Market in Asia-Pacific by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 122: Asia-Pacific Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 123: Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 AUSTRALIA Table 124: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 125: Australian Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 126: Australian Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 127: Cancer Therapies Market in Australia: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 128: Australian Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 129: Australian Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 INDIA Table 130: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 131: Indian Cancer Therapies Historic Market Review by Treatment Type in US$ Million: 2009-2017 Table 132: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 133: Indian Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 134: Indian Cancer Therapies Historic Market Review by Cancer Type in US$ Million: 2009-2017 Table 135: Cancer Therapies Market in India: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 SOUTH KOREA Table 136: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 137: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 138: Cancer Therapies Market Share Distribution in South Korea by Treatment Type: 2009 VS 2019 VS 2025 Table 139: Cancer Therapies Market in South Korea: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 140: South Korean Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 141: Cancer Therapies Market Share Distribution in South Korea by Cancer Type: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 142: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 143: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 144: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 145: Rest of Asia-Pacific Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 146: Cancer Therapies Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 147: Rest of Asia-Pacific Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 LATIN AMERICA Table 148: Latin American Cancer Therapies Market Trends by Region/Country in US$ Million: 2018-2025 Table 149: Cancer Therapies Market in Latin America in US$ Million by Region/Country: A Historic Perspective for the Period 2009-2017 Table 150: Latin American Cancer Therapies Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 151: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 152: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Treatment Type: 2009-2017 Table 153: Latin American Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 154: Latin American Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 155: Cancer Therapies Historic Market Analysis in Latin America in US$ Million by Cancer Type: 2009-2017 Table 156: Latin American Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 ARGENTINA Table 157: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 158: Cancer Therapies Market in Argentina in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 159: Argentinean Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 160: Argentinean Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 161: Cancer Therapies Market in Argentina in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 162: Argentinean Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 BRAZIL Table 163: Cancer Therapies Market in Brazil by Treatment Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 164: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Treatment Type: 2009-2017 Table 165: Brazilian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 166: Cancer Therapies Market in Brazil by Cancer Type: Estimates and Projections in US$ Million for the Period 2018-2025 Table 167: Brazilian Cancer Therapies Historic Market Scenario in US$ Million by Cancer Type: 2009-2017 Table 168: Brazilian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 MEXICO Table 169: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 170: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 171: Mexican Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 172: Cancer Therapies Market in Mexico: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 173: Mexican Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 174: Mexican Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 175: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 176: Cancer Therapies Market in Rest of Latin America by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 177: Rest of Latin America Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 178: Rest of Latin America Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2to 2025 Table 179: Cancer Therapies Market in Rest of Latin America by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 180: Rest of Latin America Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 MIDDLE EAST Table 181: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Region/Country: 2018-2025 Table 182: Cancer Therapies Market in the Middle East by Region/Country in US$ Million: 2009-2017 Table 183: The Middle East Cancer Therapies Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 184: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018 to 2025 Table 185: The Middle East Cancer Therapies Historic Market by Treatment Type in US$ Million: 2009-2017 Table 186: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Treatment Type for 2009, 2019, and 2025 Table 187: The Middle East Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018 to 2025 Table 188: The Middle East Cancer Therapies Historic Market by Cancer Type in US$ Million: 2009-2017 Table 189: Cancer Therapies Market in the Middle East: Percentage Share Breakdown of Sales by Cancer Type for 2009, 2019, and 2025 IRAN Table 190: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Treatment Type for the Period 2018-2025 Table 191: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Treatment Type for the Period 2009-2017 Table 192: Iranian Cancer Therapies Market Share Analysis by Treatment Type: 2009 VS 2019 VS 2025 Table 193: Iranian Market for Cancer Therapies: Annual Sales Estimates and Projections in US$ Million by Cancer Type for the Period 2018-2025 Table 194: Cancer Therapies Market in Iran: Historic Sales Analysis in US$ Million by Cancer Type for the Period 2009-2017 Table 195: Iranian Cancer Therapies Market Share Analysis by Cancer Type: 2009 VS 2019 VS 2025 ISRAEL Table 196: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Treatment Type: 2018-2025 Table 197: Cancer Therapies Market in Israel in US$ Million by Treatment Type: A Historic Review for the Period 2009-2017 Table 198: Israeli Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 199: Israeli Cancer Therapies Market Estimates and Forecasts in US$ Million by Cancer Type: 2018-2025 Table 200: Cancer Therapies Market in Israel in US$ Million by Cancer Type: A Historic Review for the Period 2009-2017 Table 201: Israeli Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 202: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Treatment Type for the Period 2018-2025 Table 203: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Treatment Type: 2009-2017 Table 204: Saudi Arabian Cancer Therapies Market by Treatment Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 205: Saudi Arabian Cancer Therapies Market Growth Prospects in US$ Million by Cancer Type for the Period 2018-2025 Table 206: Cancer Therapies Historic Market Analysis in Saudi Arabia in US$ Million by Cancer Type: 2009-2017 Table 207: Saudi Arabian Cancer Therapies Market by Cancer Type: Percentage Breakdown of Sales for 2009, 2019, and 2025 UNITED ARAB EMIRATES Table 208: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 209: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 210: Cancer Therapies Market Share Distribution in United Arab Emirates by Treatment Type: 2009 VS 2019 VS 2025 Table 211: Cancer Therapies Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 212: United Arab Emirates Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 213: Cancer Therapies Market Share Distribution in United Arab Emirates by Cancer Type: 2009 VS 2019 VS 2025 REST OF MIDDLE EAST Table 214: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Treatment Type for the Period 2018-2025 Table 215: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Treatment Type: 2009-2017 Table 216: Rest of Middle East Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 217: Cancer Therapies Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Million by Cancer Type for the Period 2018-2025 Table 218: Rest of Middle East Cancer Therapies Historic Market Analysis in US$ Million by Cancer Type: 2009-2017 Table 219: Rest of Middle East Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025 AFRICA Table 220: African Cancer Therapies Market Estimates and Projections in US$ Million by Treatment Type: 2018 to 2025 Table 221: Cancer Therapies Market in Africa by Treatment Type: A Historic Review in US$ Million for 2009-2017 Table 222: African Cancer Therapies Market Share Breakdown by Treatment Type: 2009 VS 2019 VS 2025 Table 223: African Cancer Therapies Market Estimates and Projections in US$ Million by Cancer Type: 2018 to 2025 Table 224: Cancer Therapies Market in Africa by Cancer Type: A Historic Review in US$ Million for 2009-2017 Table 225: African Cancer Therapies Market Share Breakdown by Cancer Type: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled : 75 (including Divisions/Subsidiaries - 80) Read the full report: https://www.reportlinker.com/p05817674/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

Read the original:
Global Cancer Therapies Industry - Yahoo Finance

Newark, NJ, Jan. 24, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal beauty and personal care products market is expected to grow from USD 493.34 billion in 2018 to USD 756.63 billion by 2026, at a CAGR of 5.81% during the forecast period 2019-2026.

Beauty and personal care products are used to enhance the appearance of the face or fragrance and texture of the body. Many beauty products are designed for applying to the face and body. They are generally mixtures of chemical compounds derived from natural sources or maybe synthetic or artificial. Nowadays, many companies are producing natural and organic beauty and personal care products, with the increasing consumer concern over chemical usage in beauty products. In addition to this, an increasing trend of personalization and customization of beauty and personal care products is expected to offer considerable opportunities in the market. Moreover, innovation in packaging of beauty products is further boosting the growth of the market, during the forecast period 20192026.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/407144/request-sample

Global Beauty and Personal Care Product Market Key Findings:

Browse full report with TOC athttps://www.fiormarkets.com/report/beauty-and-personal-care-products-market-by-product-407144.html

About the report:

The global beauty and personal care product market is analysed on the basis of value (USD Billion). All the segments have been analyzed on global, regional and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porters five forces model, attractiveness analysis, raw material analysis, supply, demand analysis, competitor position grid analysis, distribution and marketing channels analysis.

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash DHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@fiormarkets.comWeb:www.fiormarkets.com

To Know More Market Research Reports and Industry Analysis, Visit our Associate Website: https://marketandresearch.bizRelated Reports

Global Breast Cancer Liquid Biopsy Market - https://www.fiormarkets.com/report/global-breast-cancer-liquid-biopsy-market-by-circulating-376049.htmlGlobal Cell Therapy Technologies Market - https://www.fiormarkets.com/report/global-cell-therapy-technologies-market-by-product-consumables-376050.htmlGlobal Gene Therapy Market - https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.htmlGlobal Health Intelligent Virtual Assistant Market - https://www.fiormarkets.com/report/global-health-intelligent-virtual-assistant-market-by-products-376053.html

More:
Global Beauty and Personal Care Product Market is Expected to Reach USD 756.63 Billion by 2026 : Fior Markets - GlobeNewswire

The Fulton County Health Department has scheduled the following health clinics and services.

CANTON The Fulton County Health Department has scheduled the following health clinics and services. Please call the number listed with each service for an appointment or more information.

Maternal child health: Health screenings, WIC nutrition education and supplemental food coupons for women, infants and children. To make an appointment or for more information call 647-1134 (ext. 254). For Astoria clinic appointments call 329-2922.

Canton - Clinic - Monday, Jan 27 - 8-4 - Appt needed

Canton - WIC Nutrition Education - Tuesday, Jan 28 - 8-4 - Appt needed

Astoria - Clinic, WIC Nutrition Educ. - Wednesday, Jan 29 - 9-3 - Appt needed

Canton - Clinic - Thursday, Jan 30 - 8-4 - Appt needed

Adult Health Immunizations: Various vaccines are available. There is a fee for immunization administration. Medicaid cards are accepted. To make an appointment or for more information call 647-1134 (ext. 254).

Other times available by special arrangement at Canton, Cuba and Astoria.

Blood Lead Screening: Blood lead screenings are available for children ages one to six years. A fee is based on income. To make an appointment or for more information call 647-1134 (ext. 254). For Astoria appointments call 329-2922.

Family Planning: Confidential family planning services are available by appointment at the Canton office for families and males of child-bearing age. Services provided include physical exams, pap smears, sexually transmitted disease testing, contraceptive methods, pregnancy testing, education and counseling. Services are available to individuals of all income levels. Fees are based on a sliding fee scale with services provided at no charge to many clients. Medicaid and many insurances are accepted. After hours appointments are available. To make an appointment or for more information call the 647-1134 (ext. 244). *Program funding includes a grant from the US DHHS Title X.

Pregnancy testing: Confidential urine pregnancy testing is available at the Canton and Astoria offices. This service is available to females of all income levels. A nominal fee is charged. No appointment is needed. A first morning urine specimen should be collected for optimal testing and brought to the health department. Services are provided on a walk-in basis on the following days each week:

Canton: Every Wednesday & Thursday, 8-3:30 (for more information call 647-1134 ext. 244)

Astoria: Every Wednesday, 9-2:30 (for more information call 329-2922)

Womens Health: A womens clinic for pap tests, clinical breast examinations and vaginal examinations is available by appointment. There is a nominal fee for this service. Medicaid cards are accepted. Financial assistance is available for a mammogram. Cardiovascular screenings may be available to age and income eligible women. To make an appointment or for more information call 647-1134 (ext. 244).

Mammograms: Age and income eligible women may receive mammograms at no charge. Speakers are available to provide information to clubs and organizations. For more information or to apply for financial assistance, call 647-1134 (ext. 254).

Mens Health: Prostate specific antigen (PSA) blood tests are available for men for a fee. To make an appointment or for more information call 647-1134 (ext. 224).

Canton - Clinic - Monday, Jan 27 - 8-12 - Appt needed

Sexually Transmitted Disease (STD) Clinic: Confidential STD and HIV testing services are available by appointment to males and females at the Canton office. Services include physical exams to identify STDs, a variety of STD testing, HIV testing, education, counseling, medications and condoms. There is a nominal fee for services. Services are available to individuals of all income levels. Medicaid cards are accepted. To make an appointment or for more information call 746-1134 (ext. 224).

HIV Testing and Counseling: Confidential HIV testing and counseling services are available by appointment through the sexually transmitted disease (STD) clinic at the Canton office. To make an appointment or for more information call 647-1134 (ext. 224).

Tuberculosis (TB) Testing: TB skin tests are available at no charge by appointment. To make an appointment or for more information call 647-1134 (ext. 254).

Blood Pressure Screenings: The Fulton County Health Department provides blood pressure screenings at no charge on a walk-in basis during the following times:

Canton - Screening - Monday, Jan 27 - 8-5 - Walk in/Room 108

Cuba - Screening - Monday, Jan 27 - 8-12 - Walk in

Astoria - Screening - Wednesday, Jan 29 - 9-12 - Walk in

Health Watch Wellness Program: The Health Watch Program provides low cost lab services. Through this program adults can obtain venous blood draws for a variety of blood tests. Blood tests offered without a doctors order Comprehensive Metabolic Panel (CMP), Complete Blood Count (CBC), Lipid Panel, Prostate Specific Antigen (PSA) test, Hepatitis C test, and Thyroid Stimulating Hormone (TSH). A wide variety of blood tests are also available with a doctors order. There is a charge at the time of service. To make an appointment or for more information call 647-1134 (ext. 254).

Canton - Clinic - Monday, Jan 27 - 8-12 - Appt needed

Dental Services: The Dental Center offers a variety of basic dental services to children and adults. An appointment is needed. Medicaid and Kid Care cards are accepted. To make an appointment or for more information call 647-1134 (ext. 292).

Read the original post:
Health Department announces services for the week of Jan 27 - Teutopolis Press-Dieterich Gazette

In the predawn darkness, you can see an eerie red glow shining from the windows of the Hudson, Wis., home of Thaddeus Owen and his fiance, Heidi Sime.

The couple are awake, having slept in their Faraday cage a canopy over their bed that blocks electromagnetic fields like the Wi-Fi signals or radiation from cellphone towers, which they believe are harmful.

Their primal sleeping environment also has special pads under the bed that are supposed to mimic the effect of sleeping on the ground under the influence of the Earths magnetic field, thus combating Magnetic Field Deficiency Syndrome.

Their house is bathed in red light because they think white incandescent, LED and fluorescent lighting robs them of sleep-regulating melatonin hormones. They wear special sunglasses indoors for the same reason, blocking the blue light from computers, cellphones or televisions when its dark outside.

Their morning routine includes yoga in a shielded, infrared sauna designed to create an EMF-free ancestral space, and putting tiny spoonfuls of bitter white powders under their tongues. These are nootropics, so-called smart drugs, which are supposed to improve focus, mood or memory.

When day breaks, they go out in their yard and face the rising sun Thaddeus in shorts and no shirt, Heidi in a sports bra and yoga pants doing Qigong in the snow and 25-degree air.

Getting early-morning sunlight, they believe, will correctly set the circadian rhythm of their bodies. Exposing their skin to the freezing temperatures, they hope, will help release human growth hormone, stimulate their immune system and trigger the body to burn fat to heat itself.

Forget Blue Zones. This is what your morning looks like if youre biohacking your way to an optimal you.

Biohacking is a DIY biology movement that started in Silicon Valley by people who want to boost productivity and human performance and engineer away aging and ordinary life spans. Think of it as high-tech tinkering, but instead of trying to create a better phone, biohackers are trying to upgrade to a faster, smarter, longer lasting, enhanced version of themselves.

Owen, 44, describes it as a journey of self-experimentation, using practices that are not talked about by mainstream media and your family doctor. His aim is to combine the latest technology and science with ancient knowledge to modify his environment, inside and out.

My entire goal is to basically age in reverse, he said.

Aiming for supernormal

Owen, who is from New York, studied chemical engineering in college. He worked for Procter & Gamble, helping to create beauty care products, and for pharmaceutical firms, developing manufacturing processes.

Now he works from home, managing worldwide product regulations in the sustainability department for office furniture company Herman Miller. But he moonlights as a biohacking guru.

He started a Twin Cities biohacking Meetup group that organizes weekly cold-water immersions at Cedar Lake in Minneapolis. Hes given a TEDx talk urging audience members to wear blue-light-blocking glasses indoors at night.

Hes helping to organize a Cold Thermogenesis and Heat Shock retreat at the end of next month in Pequot Lakes, Minn., where 50 people will pay up to $2,300 to spend four days going on shiver walks, drinking Bulletproof coffee and plunging into ice water.

He founded the website primalhacker.com and he and the 45-year-old Sime (who also goes by the name Tomorrow) run a website called thaddeustomorrow.com, where they market biohacking products like red light panels, a baby blanket that blocks EMF radiation and a $5,499 Faraday cage sauna thats the same type used by Twitter founder Jack Dorsey.

Owen said he relies on tons of research to support avoiding blue light at night and the healing properties of the early morning sun.

The Harvard Health Letter, for example, said that blue light from devices, LED and compact fluorescent bulbs can throw off the bodys circadian rhythm, affect sleep and might contribute to cancer, diabetes, heart disease and obesity. Some studies have shown that exposing people to cold temperatures burns calories and repeated cold-water immersions might stimulate the immune system.

And those infrared saunas? They dont appear to be harmful and maybe they do some good, according to Dr. Brent Bauer, an internal medicine expert at the Mayo Clinic.

But being healthy really doesnt need to be that complicated, according to Dr. Michael Joyner, a human performance specialist at the Mayo Clinic.

All these things sound great, Joyner said of the biohacks. Theres a ring of what I call bioplausibility to them.

But Joyner said its often hard to find evidence that biohacking practices actually work and that most Americans would be healthier if they just followed basic advice.

You need to go for a walk, not smoke, not drink too much, dont eat too much, he said.

But Owens goal is not to be merely healthy.

I want my biology to be shifted to that supernormal range, where Im optimally healthy, he said.

Moving into the mainstream?

When he started biohacking about 12 years ago, Owens goal was to improve his sleep. As a competitive athlete, he was fit, but he had problems with anxiety and insomnia.

So he started wearing special glasses to block blue light. His co-workers used to think he was odd. Now Owens company is asking him for advice on what kind of lighting should be used in work settings to keep employees healthy. And his sleep and anxiety problems have gone away.

I went from being the weird guy to being consulted, he said.

We all sort of watch what he does, said Gabe Wing, director of sustainability at Herman Miller and Owens boss. Wing said Owen has influenced some co-workers to try blue-light-blocking tools. But no one at the Michigan-based company is going outside shirtless in the winter.

Still, more people are biohacking. When Owen first got into it, he didnt know of any other biohackers in the Twin Cities. Now there are more than 500 people in the Biohackers Twin Cities Meetup group.

Susan Eiden regularly gets advice from Owen. The Minneapolis resident said using red lights at home has drawn comments from neighbors, but the lights combined with blue-blocking glasses and turning off the Wi-Fi at night have improved her sleep.

While many biohacks seem odd now, Owen is convinced that some of them will become common practices.

This whole blue light thing, its not going away, he said. More research comes out every day and its becoming more mainstream. And using nootropics is growing bigger and bigger every day, he said.

Owen takes supplements, some of which are considered prescription drugs in Europe and Russia, like phenylpiracetam, which is said to have boosted stamina among Soviet cosmonauts. Other preclinical compounds he and Sime use are in a regulatory gray area in the United States. Nootropic developers give them supplements that arent on the market yet because theyre biohacking influencers.

Were like lab rats. They send us stuff. We try it out, Sime said.

All for longevity

Owen and Sime have five of their children, ages 8 to 17, living with them. The kids wear blue-light-blocking glasses when they watch TV, but theyre OK with it, the couple said. Some of the kids have made videos or given talks to peers about the benefits of the glasses.

I think cellphone radiation is going to be the new lead, asbestos and smoking, said Owen, who turns his Wi-Fi off at night, keeps his cellphone in a special Faraday pouch when he sleeps and sometimes wears radiation-proof underwear.

(The National Institute of Environmental Health Sciences says scientific evidence has not conclusively linked cellphone use with any adverse human health problems, although scientists admit that more research is needed.)

Owens diet isnt typical, either.

Hes been a vegan and a vegetarian. Now he eats what he describes as a local, seasonal diet: local vegetables, fruits, nuts and honey during the growing season. Thats followed by a high-fat, low-carb ketogenic diet in late fall and early winter. Then an all-carnivore diet in late winter, including animals hes raised at a friends farm.

One of the few white light bulbs he has in his house is pointed at the stove because in red light, its hard to tell if meat is cooked.

He also consumes ceremonial grade cacao, coffee with collagen peptides and chocolate ghee and homemade sauerkraut thats fermented and subjected to special music that has the frequency of love.

Those are living microbes, so I infused them with a love frequency to make them happy and healthy, said Owen, who has a masters degree in holistic nutrition.

While he used to do marathons and triathlons, he now exercises for longevity rather than competition, with high-intensity training, weights, racquetball and cross-country skiing.

If its too cold to be barefoot when he goes out in the morning, hell put special straps on his boots to create a conductive connection between his body and the Earth.

Its a practice called grounding or Earthing thats supposed to allow electrons to pass between the Earth and his body to reduce inflammation and neutralize free radicals. Gwyneth Paltrow swears by it, according to an article on goop.com.

Owen doesnt have a particular longevity goal, unlike biohacker and Bulletproof Coffee founder Dave Asprey, who has said he wants to live to at least 180.

Owen just wants to be healthy and independent for as long as he lives.

I want to maximize the health of my biology to what its capable of, he said. I want to live the best life that I can. I want to be happy. And I want to have a body and a mind that does the things I want them to do.

More:
Sleep cages and ice baths: The extreme lifestyle of local biohackers - Minneapolis Star Tribune

Between 2000 and 2012, the Department of Veterans Affairs reported a 327% increase in anxiety disorders among military members. A recent study suggests that this may be due to the discovery of a so-called "worry gene." Researchers from Yale University in New Haven, Connecticut, and the University of California in San Diego analyzed the genes of 200,000 U.S. veterans and identified six genetic variants linked to anxiety a discovery that may help explain why anxiety and depression often go hand in hand.

The study authors hailed their finding as "the richest set of results for the genetic basis of anxiety to date." But leading psychologists say that while genes may load the gun, it's most often environment that pulls the trigger on mental health disorders.

According to Mental Health First Aid, 20 veterans die by suicide each day. Over 30% of active duty and military personnel deployed in Iraq and Afghanistan have a mental health problem requiring treatment, but only half of these returning veterans receive the care they need.

"We should spend as much money on helping these veterans re-enter their civilian lives as we do in training them for the military," Dr. Terry Lyles, Ph.D., an internationally recognized expert on dealing with trauma and stress, tells Newsmax. "The study points the finger at genetics on why our military personnel have mental health issues. However, we basically all have the same genetic patterns but when threatened with violence, danger, and combat stress, we release levels of cortisol, the stress hormone, that drains our bodies of the natural resources to deal with that constant bombardment.

"Cortisol literally eats serotonin, the hormone that helps regulate mood and social behavior. So, when these veterans are subjected to constant threats, improper nutrition, lack of sleep, and sunlight it's no wonder they become rewired to exhibit anxiety and depression."

Lyles, known as America's "Stress Coach," uses highly specialized techniques to help veterans and other individuals such as the rescue workers at Ground Zero and those in the tsunami-torn area in Asia to help channel mental negativity and chaos into more productive and positive pathways.

Dr. Lois Mueller, a clinical psychologist from Tampa who worked at the U.S, Department of Veterans Affairs, Outpatient Clinic for 10 years, tells Newsmax, that people with a genetic predisposition toward anxiety will have a 10-fold increased risk of developing a mental disorder when being placed in a combat situation where people around you are wounded or dying.

"Whatever they came with genetically was certainly affected by their environment," she says. "The proof of impact of combat would be to compare vets before being in the military and five years after combat. Don't forget, a lot more were traumatized not only by combat itself but also by associated military duties such as picking up and bagging bodies or delivering the folded flags to mothers here in the States.

"My experience with vets with PSTD is very often people who were calm and worry-free prior to combat ended up anxious and fearful after leaving the military. Early treatment can make a difference but length of exposure to combat can make it very difficult to eliminate the problem. We are still learning about treatment techniques."

2020 NewsmaxHealth. All rights reserved.

Read more:
Solving Depression and Anxiety in Veterans - Newsmax

In the largest genetics study of its kind to date, scientists have identified 102 genes associated with the risk for autism spectrum disorder (ASD).

Researchers also gained further insight into which of these genes are associated with both ASD and other disorders that cause intellectual disability and developmental delay.

For the study, an international team of researchers analyzed more than 35,000 participant samples, including almost 12,000 from people with ASD.

Researchers used a genetic technique called exome sequencing, which looks at all the regions of a persons genetic information or genome that are translated into proteins. This testing can pick up rare genetic mutations that might not show up with other methods.

Dr. Lonnie Zwaigenbaum, a professor in the Department of Pediatrics and the Stollery Childrens Hospital Foundation Chair in Autism at the University of Alberta, called this an exciting study, both for the sophisticated methods used and the large sample size.

These enabled researchers to identify a larger number of genes than ever before, which gives insight into how those genes operate and how they might increase the risk of ASD, said Zwaigenbaum, who wasnt involved in the research.

The study results were published January 23 in the journal Cell.

ASD is a group of neurological and developmental conditions that affect communication and behavior. Theres wide variation in the type and severity of symptoms in people with ASD.

Scientists believe that both genes and environment are involved in the development of ASD, with genetics playing a big part.

We know that inherited and unique mutations in the genome are a major source of risk for developing ASD, but specific causes of ASD are not yet well understood, said Lori J. Warner, PhD, director of the Center for Human Development and Ted Lindsay Foundation HOPE Center at Beaumont Childrens Hospital in Royal Oak, Michigan, who wasnt involved in the study.

Although environmental factors play some role in ASD, scientific studies have found that theres no link between receiving vaccines and developing ASD.

The new study marks an important step forward in scientists understanding of the genetic basis of ASD.

Researchers identified both inherited genetic mutations and de novo mutations ones that occur spontaneously when an egg or sperm form.

They also found that the ASD genes identified in the study can affect brain development or brain function. And they showed that two major types of nerve cells can be affected in ASD.

Of the 102 genes identified in the study, 49 were associated with other developmental delays.

Some genes appear connected to the development of ASD, whereas others may increase risk for ASD plus severe neurodevelopmental disorder, said Warner. We dont yet understand fully this process, but differentiating ASD from other disorders is important for effective treatment.

Zwaigenbaum said the overlap between ASD and other neurodevelopmental disorders fits with previous research.

This study reinforces that there are many genes that may have some role in autism vulnerability, but that also have a broader role in early brain development, said Zwaigenbaum.

These genes have a broader expression in terms of developmental abilities and challenges of the affected individual.

While scientists now understand ASD better as a result of this study, this kind of research also points toward better ways to help children with ASD.

The greatest benefit of studies of this type is helping researchers, families, and interventionists better understand how genetic factors actually function in the developing brain and body of the individual, said Warner, so that treatments can be developed to ameliorate or completely block the disruptive changes that lead to disorders such as ASD.

But Zwaigenbaum cautions that the results of the study will not lead to clinical benefits right away.

Theres a lot of translational work that would still need to happen in order to assess whether the findings from this study will directly inform assessment, diagnosis, or treatment, he said.

Still, he said the results provide direction for future research into potential biological treatments, as well as genetic tests that could allow earlier diagnosis of ASD.

Warner said there are medications currently approved for use in children with ASD, but they address symptoms like agitation or anxiety, rather than the core social or behavioral deficits of ASD.

Early diagnosis is another goal of ASD research, because the sooner children are identified and appropriately assessed, the sooner families can receive needed supports, said Warner.

But ASD is a complex condition, so genetic diagnosis isnt always straightforward.

Although studies like this continue to expand our appreciation for the increasing number of genes associated with ASD, the reality is that a genetic cause is seldom identified in most children with ASD even with the most sophisticated genetic testing, said Andrew Adesman, MD, chief of Developmental & Behavioral Pediatrics at Cohen Childrens Medical Center in Queens, New York, who wasnt involved in the study.

But he said theres still value in parents of a child with ASD seeking out genetic testing, especially as genetic technologies advance.

There have been steady gains in terms of the diagnostic yield of genetic testing, said Adesman. For this reason, parents of children with ASD may wish to discuss with their pediatrician whether their child should have the newer genetic tests done.

In the absence of a simple test for ASD, there are still things parents can do for their children.

The single most important things families and healthcare providers can do is to be aware of the risk factors and early signs and symptoms of autism, and get connected with needed services as soon as possible, said Warner.

Continue reading here:
What Causes Autism? Researchers ID 102 Genes Linked to Condition - Healthline

Thursday, January 23, 2020

Florida could be the first state to deny life and long-term care insurers access to genetic test results. Under a new bill titled Genetic Information for Insurance Purposes (HB 1189), life insurers and long-term care insurers are prohibited from canceling, limiting, or denying coverage, or establishing differentials in premium rates based on genetic information. In addition, HB 1189 would prevent life insurers and long-term care insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or actions relating to genetic testing in any manner for any insurance purposes.

On Jan. 16, the Florida House Health & Human Services Committee passed HB 1189 without any debate. The bill is now being reviewed by the Commerce Committee, which will have to clear the bill before it would be ready to go to the full House.

HB 1189 is sponsored by Representative Chris Sprowls, the incoming Speaker-designate. It is the only bill he has filed this year. In the Senate, the bill is sponsored by Kelli Stargel, who is part of Senate leadership. Given HB 1189s sponsors, the issue will likely be a high profile one, and will have a good chance of passing in the next year or two.

Existing federal law, the Genetic Information Nondiscrimination Act (GINA), protects Americans from discrimination in health insurance, employment decisions, and employee benefit decisions on the basis of genetic information. Under GINA, U.S. insurance companies and health plans (including both group and individual insurers, as well as federally regulated plans) are prohibited from:

looking at predictive genetic information or genetic services before enrollment;

requesting or requiring that individuals or their family members take a genetic test;

restricting enrollment based on genetic information;

changing premiums based on genetic information.

GINA, however, does not cover life, long-term care, or disability insurance providers. As a result, those companies can ask about health, family history of disease, or genetic information, and reject those that are deemed too risky.

2020 Greenberg Traurig, LLP. All rights reserved.

Read more from the original source:
Genetic Non-Discrimination Bill Advances in Florida - The National Law Review

As the threats of cyberattacks now loom large in the aftermath of recent U.S. tensions in the Middle East, caution is needed with recreational use of genetic testing.

Just a month ago, on Dec. 20, a memorandum advising U.S. military personnel to refrain from the purchase or use of direct-to-consumer (DTC) genetic testing services was sent to a wide Defense Department distribution list. This memo came from the U.S. Under Secretary of Defense for Intelligence Joseph D. Kernan and Assistant Secretary of Defense for Manpower and Reserve Affairs James N. Stewart. This was a wise move, as Kernan and Stewart reminded their audience that this largely unregulated DTC genetic testing industry poses potential risks to individual privacy and to national security that could affect military operational readiness.

Privacy considerations and readiness issues are raised by DTC genetic testing of military service members, and major security concerns are at hand.

We already know that foreign governments are exploiting various surveillance methods, including DNA-typing, for monitoring individuals without their consent. There are well-known national security concerns that biological weapons can target specific groups or individuals who are genetically vulnerable to the effects of weaponized pathogens or other diseases. Besides these concerns, large-scale DNA typing affords use of genetic data for individualized identification, permits identification of unexpected parentage and family relationships, and exploits the ability to estimate bio-geographic ancestry.

While some of these genetic data generated are useful for various recreational purposes and for certain forensic investigations, unauthorized hacking of the data on military members could compromise national security for covert operators and for unit cohesion and mission readiness.

Two facts about genetic testing in military health settings are not well-appreciated.

First, protections of the Genetic Information Nondiscrimination Act (aka GINA), signed into law by President George W. Bush, do not apply to the military. While there are some policies in place to deal with genetic health information for service members, some genetic testing results, for example the finding of sickle cell trait, can place restrictions on some members with aviation specialties.

Get the military's most comprehensive news and information every morning

(please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Subscribe

By giving us your email, you are opting in to the Early Bird Brief.

Second, U.S. DoD policies (i.e., DodI 6025.19) require service members to report (any) medical and health issues that may affect their individual readiness to deploy to serve on active status and to report any significant health information up the chain-of-command.

These realities present conundrums for those serving on active status in the military. This is due to the large amount of genetic data that are assessed by the DNA companies, often then shared electronically with other companies from the saliva or cheek swab samples they collect.

Depending on the testing kit and service requested by the consumer, genetic disease carrier state and health risk information is often communicated, but not necessarily confirmed or validated by another method, nor are new tests necessarily even reviewed by the FDA before being offered. Such testing results, if affecting a large fraction of those serving in a military unit be it a squad, platoon or company could easily interfere with critical missions if the purported results require verification by followup testing or clinical evaluation of the service member.

These matters concern all of us. Our passion for freedom requires us to walk the long and winding road to digital freedom. We must more carefully examine the commercial interests of DTC companies and the security of the genetic data they control as we balance interests in privacy of our service members and our national security, too often threatened and those of privacy rights, too often denied.

Frederick R. Bieber, Ph.D., is a forensic DNA-expert and member of the faculty of medicine at Harvard University. He served as a U.S. Army Reserve officer at the U.S. DoD DNA-Identification Laboratory (AFDIL) in Rockville, Maryland, the Dover AFB Mortuary, and at the U.S. Army Criminal Investigation Laboratory (USACIL) at Fort Gillem, Georgia.

Editors note: This is an Op-Ed and as such, the opinions expressed are those of the author. If you would like to respond, or have an editorial of your own you would like to submit, please contact Military Times managing editor Howard Altman, haltman@militarytimes.com.

More here:
Digital freedom and DNA: Caution advised on the road ahead - Military Times

Lets say, for the holidays, you got a kit from Ancestry.com, 23andMe or a similar company to send in your DNA (aka your spit) and discover your roots as well as your personalized health report.

You spit, you send it off, and youre starting to get the results back.

And in that personalized health report, theres an indication for an increased cancer risk, or theres no indication of an increased cancer risk ... now what? Can these reports be believed? Should you go running to find the nearest doctor to prevent your impending death?

Gayle Patel, a certified genetic counselor and the director of the Genetic Risk Evaluation and Testing Program at Texas Oncology, wants people to know these tests arent looking at the whole genome. Theres a limit to what it can do, she says, but they might come up with some interesting health traits, as well as your long-lost ancestors.

Some of the mysteries they can solve, such as whether there is a genetic reason you prefer chocolate or vanilla ice cream, can be fun, she says. But its not telling the whole story.

If results from one of these tests show an increased risk for something, she recommends bringing that information to your doctor at your next appointment. Its not that you have a disease but that you may have an increased risk, she says.

Your doctor will want to assess what the risk is, how accurate it is and what preventative steps you might want to take, she says.

These boxed ancestry/DNA tests dont have the experts who can personalize the test for you based on your medical and family histories. They also dont have a person explain it to you and make a plan for you.

It can be difficult and scary, she says, to get these results. None of this is destiny or fate. Its talking to you about personalizing your medical care.

Her bigger concern is not that these tests are going to find a risk; its that they wont find a risk and you will think you are fine and not do the usual preventative treatments or recommended screenings.

For example, about a year ago, 23andMe added some of the BRCA mutations to what it looks for. BRCA mutations indicate a risk for breast cancer and ovarian cancer. Patel says this test now is looking at only three of the mutations when there are thousands. Weve had patients who think they have tested negative for that type of cancer when its not true.

Instead, based on personal medical history and family history, shell recommend doing a medical-grade test in an office that specializes in genetic testing to get a comprehensive look at all types of cancer risks.

Were either going to confirm or make sure were not missing something else that can be just as important, Patel says.

Medical testing has gone down in price, and this kind of genetic testing now can be done for about $250, she says, which is about the price of the 23andMe or Ancestry.com kit that includes health DNA. Often, based on medical history, insurance will cover the medical tests.

Patel also wants folks to realize that only about 5% to 10% of all cancers have a known genetic component. Of course, it depends on the type of cancer. Ovarian cancer has about a 23% genetic link, she says, but lung and cervical cancer tend to be more environmental and less likely to be genetic.

New gene mutations are being discovered all the time as more and more data is collected, and what genetics counselors can test for changes all the time, too.

Patel also recommends reading the fine print of where your DNA data is being stored by these companies. Who owns the data, and how is the data being shared? It might be going to a database accessed by pharmaceutical companies for research on new cancer treatments, or it might be on an open database accessible to anyone. As long as they are informed and educated, she says, then these tests are OK. Learn before they spit.

As well, be prepared for the results you might get, such as a long-lost brother or that your father isnt your biological father. It could be one of these surprises that could change how you think about your family, she says.

More:
What 23andMe, Ancestry.com kits arent telling you about your health risks - austin360

Researchers have identifiedmore than 100 genes associated with autism in the largest genetic-sequencing study to date that could help shed light on the causes of the condition.

In a study published Thursday in the peer-reviewed journal Cell, a team of researchers identified 102 genes associated with the risk of autism spectrum disorder (ASD), using samples from more than 35,000 participants, 12,000 of which had autism. They were able to study genes that were inheritedas well as those that occurred spontaneously when the egg or sperm is formed.

The study shows progress toward teasing apart genes associated with ASD from those associated with intellectual disability and developmental delay, conditions that often overlap.

Of the 102 genes associated with ASD risk, 49 were also associated with other developmental delays.

With these identified genes we can begin to understand what brain changes underlie ASD and begin to consider novel treatment approaches, Joseph Buxbaum, the director of the Seaver Autism Center for Research and Treatment at Mount Sinai, said in a statement.

ASDis a developmental disorder that affects communication and behavior, and although autism can be diagnosed at any age, it is said to be a developmental disorder because symptoms generally appear in the first two years of life.

The Centers for Disease Control and Preventionestimates that about 1 in 59 children has been identified with ASD.

Researchers said the results were encouraging as genetic testing could increase the likelihood of figuring out the cause of some childrens autism.

Through our genetic analyses, we discovered that its not just one major class of cells implicated in autism, but rather that many disruptions in brain development and in neuronal function can lead to autism, Buxbaum said. We now have specific, powerful tools that help us understand those underpinnings, and new drugs will be developed based on our newfound understanding of the molecular bases of autism.

Visit link:
Researchers identify more than 100 genes associated with autism - The Hill

Chicago, United States, Jan 22, 2020 Report Hive Research adds Breast Cancer Predictive Genetic Testing market report to its market research database. This report is a detailed study of core market elements which represents concise analysis of the growth factors impacting the business scenario in the next five years to come. Breast Cancer Predictive Genetic Testing Market covers major assorted regions across the globe along with providing in depth regional analysis for every region ranging from North America, Europe, South America, MEA and Asia-Pacific depending on the report specifications mentioned in the table of content.

Breast Cancer Predictive Genetic Testing market report provides substantial information on the industry size, share, trends and applications; further offering vital statistics to market players and investors. Such information poses a high level of accuracy as the data is sourced from reliable entities and figures denoted are summed after extensive market analysis. The data obtained from the report eases of predicting upcoming market opportunities.

In this report, our team research the global Breast Cancer Predictive Genetic Testing market by type, application, region and manufacturer 2014-2020 and forcast 2021-2026. For the region, type and application, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers sales, price, revenue, cost and gross profit and their changes. Whats more, we will display the main consumers, raw material manufacturers, distributors, etc.

Download PDF Sample of this Report @ https://www.reporthive.com/request_sample/2144051

Furthermore, the brief competitive analysis included in the study illustrates the current status of major market players along with their expansion strategies and portfolio developments. Breast Cancer Predictive Genetic Testing market is bound to witness significant gains and is predicted to register a substantial CAGR in the years to come. The statistical graphs and figures included in this report displays global market share in term of sales and revenue.

Encompassing a comprehensive overview on market size, share and growth opportunities, Breast Cancer Predictive Genetic Testing market report allows to garner detailed insights on segmental growth which is propelled by specific applications in the key regions and countries as per denoted in the table of content. For this, the report considers market volumes and numbers generated from the segmental analysis.

Such segmentation uncovers various hidden trends and market statistics that may highly influence the decisions of various participants, including investors and new market entrants. The report also presents detailed analysis of the major vendors and manufacturers in the market further proving helpful to the start-ups looking to set up their business portfolios in the Breast Cancer Predictive Genetic Testing market.

Get Detailed Overview of this Report: https://www.reporthive.com/Report/2144051/Breast-Cancer-Predictive-Genetic-Testing-Market

Finally, the report decisively elaborates on key drivers which are set to augment Breast Cancer Predictive Genetic Testing market growth during the forecast timeframe. Along with this, it briefs on both the opportunities and challenges that likely to impact the business growth and the market as a whole. Pointing toward key emerging trends and their impacts on present and future prospects this comprehensive study helps sustaining the extremely competitive landscape by enabling to plan accordingly as per the market conditions.

Leading players of Breast Cancer Predictive Genetic Testing including:

RocheThermo Fisher ScientificPerkinElmerQuest DiagnosticsMyriad GeneticsIverson GeneticsCancer GeneticsOncoCyte CorporationNeoGenomicsInvitae

Market split by Type, can be divided into:

High Penetrant GenesIntermediate Penetrant GenesLow Penetrant Genes

Market split by Application, can be divided into:

HospitalsClinicsOther

If you have any special requirements, please let us know and we will offer you the report as you want.

Get Customized PDF of this Report @ https://www.reporthive.com/request_customization/2144051

About Us

Report Hive Research is a comprehensive repository of market intelligence reports based on emerging trends and latest data sourced from across the globe. Our database holds more than 700000+ research reports delivered by globally renowned publishers. The repository is consistently analysed and updated to make sure our clients receive access to the latest insights on global industries, companies, and products. Apart from this, we also specialize in report customization which expands our reach to research industry, thus meeting the specific requirements of our esteemed clients.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See the article here:
Breast Cancer Predictive Genetic Testing Market Product and Application Segmentation till 2020 Dagoretti News - Dagoretti News

Growing up, cancer for me was something that old people got. I lost my maternal grandmother before I even got a chance to meet her, my paternal grandfather by the time I was six and my paternal grandmother at 13.

It wasn't until my mother was diagnosed with brain cancer at the age of 48 that it became real: this disease doesn't just hit elderly people.

My mother's cancer was a rare one: hemangiopericytoma, a type that can be dormant for long periods of time. She went through brain surgery, radiation andlost the vision in her left eye. She ultimately kicked that cancer in the butt.

But it wasn't long after that my mother's cousins were diagnosed with cancers of their own all three before turning 55. All of their mothers had died from cancers similar to the ones they were now diagnosed with.

The similarities were too much for one of my cousins who worked in the healthcare field. With the help of her doctor, they figured out that Lynch Syndrome runs in my family.

Join CBC Saskatchewan's Sam Maciag for the January edition of The Novel Idea Society book club. This month, we'll be readingDaughter of Family G: A Memoir of Cancer Genes, Love and Fateby Ami McKay, which deals with the topic of Lynch Syndrome.

Lynch Syndrome gives the carrier a genetic predisposition to a laundry list of different cancers, meaning there's a mutation in their genes that makes them more likely to become ill. And it's hereditary.

Lynch Syndrome can be identified through the same genetic testing process as the breast cancer BRCA gene test, which has surged in popularity since Angelina Jolie came out about her genetic history.

It wasn'thelpful that my entire family is in Ontario, where the high population causes more roadblocks to testing.

Here in Saskatchewan, it starts with your family doctor, then testing in Saskatoon. When you start genetic testing, you have a counselling session to prepare you for the information you could find out. I feel like my attitude of "it's not 'if,' it's 'when'" prepared me for this meeting. Since my mom was diagnosed the first time I truly believed that it was an "I will get cancer in my lifetime" situation.

I also had made the decision early in my life that children were not for me, so having a hysterectomy or mastectomy wasn't a major concern. These are preventative surgeries that you can have if you are positive about your genetic makeup, to help you with your chances of avoiding the cancers that affect these organs.

I've taken a different approach, though.

At the same time my cousins and motherwere going through their genetic testing, I stumbled into an online test group with a health and fitness professional, which led me to understand more about how diet could play a role in my health and my fight against cancer.

My mother was diagnosed with HER2+ breast cancer during this time of discovery. This was a hard one. The accessibility to information that the Internet provided wasn't always a benefit to her mentally during this fight. It provided her with a black hole of information, very little of which waspositive.

I was also an adult this time around, which gave me more insight into what was going on. Seeing her struggle through the fight the second time really pushed me to start researching ways to make my body somewhere cancer doesn't want to grow.

Knowing what is in my family history has given me two options: either cause me to live in fear or push me to educate myself on what I can do to give me the best chance to live a long life. I personally have chosen option two and used it as a way to help others succeed in their lives.

This column is part of CBC'sOpinionsection. For more information about this section, please read thiseditor's blogand ourFAQ.

Interested in writing for us? We accept pitches for opinion and point-of-view pieces from Saskatchewan residents who want to share their thoughts on the news of the day, issues affecting their community or who have a compelling personal story to share. No need to be a professional writer!

Read more about what we're looking for here, then emailsask-opinion-grp@cbc.cawith your idea.

The rest is here:
My genes are stacked against me; it's made me a fighter - CBC.ca

What exactly is biotechnology, and how could it change our approach to human health?

As the age of big data transforms the potential of this emerging field, members of the World Economic Forum's Global Future Council on Biotechnology tell you everything you need to know.

Elizabeth Baca, Specialist Leader, Deloitte Consulting, and former Deputy Director, California Governors Office of Planning and Research & Elizabeth ODay, Founder, Olaris, Inc

What if your doctor could predict your heart attack before you had it and prevent it? Or what if we could cure a childs cancer by exploiting the bacteria in their gut?

These types of biotechnology solutions aimed at improving human health are already being explored. As more and more data (so called big data") is available across disparate domains such as electronic health records, genomics, metabolomics, and even life-style information, further insights and opportunities for biotechnology will become apparent. However, to achieve the maximal potential both technical and ethical issues will need to be addressed.

As we look to the future, lets first revisit previous examples of where combining data with scientific understanding has led to new health solutions.

Biotechnology is a rapidly changing field that continues to transform both in scope and impact. Karl Ereky first coined the term biotechnology in 1919. However, biotechnologys roots trace back to as early as the 1600s when a Prussian physician, Georg Ernst Stahl, pioneered a new fermentation technology referred to as zymotechnology.

Over the next few centuries, biotechnology was primarily focused on improving fermentation processes to make alcohol and later food production. With the discovery of penicillin, new applications emerged for human health. In 1981, the Organization for Economic Cooperation and Development (OECD) defined biotechnology as, the application of scientific and engineering principles to the processing of materials by biological agents to provide the goods and services.

Today, the Biotechnology Innovation Organization (BIO) defines biotechnology as technology based on biology - biotechnology harnesses cellular and biomolecular processes to develop technologies and products that help improve our lives and the health of our planet.

In the Fourth Industrial Revolution, biotechnology is poised for its next transformation. It is estimated that between 2010 and 2020 there will be a 50-fold growth of data.

Just a decade ago, many did not even see a need for a smart phone, whereas today, each click, step we take, meal we eat, and more is documented, logged and analyzed on a level of granularity not possible a decade ago.

Concurrent with the collection of personal data, we are also amassing a mountain of biological data (such as genomics, microbiome, proteomics, exposome, transcriptome, and metabolome). This biological-big-data coupled with advanced analytical tools has led to a deeper understanding about fundamental human biology. Further, digitization is revolutionizing health care, allowing for patient reported symptoms, feelings, health outcomes and records such as radiographs and pathology images to be captured as mineable data.

As these datasets grow and have the opportunity to be combined, what is the potential impact to biotechnology and human health? And better still, what is the impact on individual privacy?

Disclaimer: The authors above do not necessarily reflect the policies or positions of the organizations with which they are affiliated.

Image: Infographic developed by the California Biotechnology Foundation: A special thank you to Patricia Cooper, Executive Director, California Biotechnology Foundation

Daniel Heath, Senior Lecturer in the University of Melbourne's Department of Biomedical Engineering & Elizabeth Baca & Elizabeth ODay

One of the most fundamental and powerful data sets for human health is the human genome. DNA is our biological instruction set composed of billions of repeating chemical groups (thymine, adenine, guanine, and cytosine) that are connected to form a code. A persons genome is the complete set of his or her DNA code, ie the complete instructions to make that individual.

DNA acts as a template to produce a separate molecule called RNA through the process of transcription. Many RNA molecules in turn act as a template for the production of proteins, a process referred to as translation. These proteins then go on to carry out many of the fundamental cellular tasks required for life. Therefore any unwanted changes in DNA can have downstream effects on RNA and proteins. This can have little to no effect or result in a wide range of diseases such as Huntingtons disease, cystic fibrosis, sickle cell anaemia, and many more.

Genomic sequencing involves mapping the complete set, or part of individuals DNA code. Being able to detect unwanted changes in DNA not only provides powerful insight to understand disease but can also lead to new diagnostic and therapeutic interventions.

The first human genome sequence was finished in 2003, took 13 years to complete, and cost billions of dollars. Today due to biotech and computational advancements, sequencing a persons genome costs approximately $1,000 and can be completed in about a day.

Important milestones in the history of genomics

1869 - DNA was first identified

1953 - Structure of DNA established

1977 - DNA Sequencing by chemical degradation

1986 - The first semi-automated DNA sequencing machine produced

2003 - Human genome project sequenced first entire genome at the cost of $3 billion

2005 - Canada launches personal genome project

2007 - 23andMe markets first direct to consumer genetic testing for ancestry of autosomal DNA

2008 - First personal genome sequenced

2012 - England launched (and finished in 2018) 100K genome project

2013 - Saudi Arabia launched the Saudi Human Genome Program

2015 - US launched plan to sequence one million genomes

2015 - Korea launched plan to sequence 10K genomes

2016 - US launched All of Us Research cohort to enroll one million or more participants to collect lifestyle, environment, genetic, and biologic data

2016 - China launched the Precision Medicine initiative with 60 billion RMB

2016 - France started Genomic Medicine 2025 Project

Treatments available today due to DNA technology

Knowing the structure and function of DNA has also enabled us to develop breakthrough biotechnology solutions that have greatly improved the quality of life of countless individuals. A few examples include:

Genetic screenings for diseases. An individual can scan his or her DNA code to look for known mutations linked to disease. Newborns are often screened at birth to identify treatable genetic disorders. For instance, all newborns in the US are screened for a disease called severe combined immunodeficiency (SCID). Individuals with this genetic disease lack a fully functional immune system and usually die within a year, if not treated. However, due to regular screenings, these newborns can receive a bone marrow transplant, which has a more than 90% of success rate to treat SCID. A well-known example in adults is screening women for mutations in the BRCA1 and BRCA2 genes as risk factor for developing breast cancer or ovarian cancer.

Recombinant protein production. This technology allows scientists to introduce human genes into microorganisms to produce human proteins that can be introduced back to patients to carry out vital functions. In 1978, the company Genentech developed a process to recombinantly produce human insulin, a protein needed to regulate blood glucose. Recombinant insulin is still used to treat diabetes.

CAR T cells. CAR T cell therapy is a technique to help your immune system recognize and kill cancer cells. Immune cells, called T-cells, from a cancer patient are isolated and genetically engineered to express receptors that allow them to identify cancer cells. When these modified T cells are put back into the patient they can help find and kill the cancer cells. Kymriah, used to treat a type of leukemia, and Yescarta, used to treat a type of lymphoma are examples of FDA approved CAR T cell treatments.

Gene therapy. The goal of gene therapy is to replace a missing or defective gene with a normal one to correct the disorder. The first in vivo gene therapy drug, Luxterna, was approved by the FDA in 2017 to treat an inherited degenerative eye disease called Lebers congenital amaurosis.

Disclaimer: The authors above do not necessarily reflect the policies or positions of the organizations with which they are affiliated.

Frontiers in DNA technology

Our understanding of genetic data continues to lead to new and exciting technologies with the potential to revolutionize and improve our health outcomes. A few examples being developed are described below.

Organoids for drug screening. Organoids are miniature and simplified organs that can be developed outside the body with a defined genome. Organoid systems may one day be used to discover new drugs, tailor treatments to a particular persons disease or even as treatments themselves.

CRISPR-Cas9. This is a form of gene therapy - also known as genetic engineering - where the genome is cut at a desired location and existing genes can either be turned off or modified. Animal models have shown that this technique has great promise in the treatment of many hereditary diseases such as sickle cell disease, haemophilia, Huntingtons disease, and more.

We believe sequencing will become a mainstay in the future of human health.

While genomic data is incredibly insightful, it is important to realize, genomics rarely tells the complete story.

Except for rare cases, just because an individual has a particular genetic mutation does not mean they will develop a disease. Genomics provides information on what could happen to an individual. Additional datasets such the microbiome, metabolome, lifestyle data and others are needed to answer what will happen.

Disclaimer: The authors above do not necessarily reflect the policies or positions of the organizations with which they are affiliated.

Elizabeth ODay & Elizabeth Baca

The microbiome is sometimes referred to as the 'essential organ', the'forgotten organ', our 'second genome' or even our 'second brain'. It includes the catalog of approximately 10-100 trillion microbial cells (bacteria, archea, fungi, virus and eukaryotic microbes) and their genes that reside in each of us. Estimates suggest we have 150 times more microbial DNA from more than 10,000 different species of known bacteria than human DNA.

Microbes reside everywhere (mouth, stomach, intestinal tract, colon, skin, genitals, and possibly even the placenta). The function of the microbiome differs according to different locations in the body and with different ages, sexes, races and diets of the host. Bacteria in the gut digest foods, absorb nutrients, and produce beneficial products that would otherwise not be accessible. In the skin, microbes provide a physical barrier protecting against foreign pathogens through competitive exclusion, and production of antimicrobial substances. In addition, microbes help regulate and influence the immune system. When there is an imbalance in the microbiome, known as dysbiosis, disease can develop. Chronic diseases such as obesity, inflammatory bowel disease, diabetes mellitus, metabolic syndrome, atherosclerosis, alcoholic liver disease (ALD), nonalcoholic fatty liver disease (NAFLD), cirrhosis, hepatocellular carcinoma and other conditions are linked to improper microbiome functioning.

Milestones in our understanding of the microbiome

1680s - Dutch scientist Antonie van Leeuwenhoek compared his oral and fecal microbiota. He noted striking differences in microbes between these two habitats and also between samples from individuals in different states of health.

1885 - Theodor Escherich first describes and isolates Escherichia coli (E. coli) from the feces of newborns in Germany

1908 - Elie Metchnikoff, Russian zoologist, theorized health could be enhanced and senility delayed by bacteria found in yogurt

1959 - Germ-free animals (mice, rats, rabbits, guinea pigs, and chicks) reared in stainless steel in plastic housing to study the effects of health in microbe-free environments

1970 - Dr. Thomas D. Luckey estimates 100 billion colonies of microbes in one gram of human intestinal fluid or feces.

1995 - Craig Venter and a team of researchers sequence the genome of bacterium Haemophilus influenza, making it the first organism to have its genome completely sequenced.

1996 - The first human fecal sample is sequenced using 16S rRNA sequencing.

2001- Scientist Joshua Lederberg credited with coining term microbiome.

2005 - Researchers identify bacteria in amniotic fluid of babies born via C-section

2006- First metagenomic analysis of the human gut microbiome is conducted

2007- NIH sponsored Human Microbiome Project (HMP) launches a study to define how the microbial species affect humans and their relationships to health

2009- First microbiome study showing an association between gut microbiome in lean and obese adults

2011- German researchers identify 3 enterotypes in the human gut microbiome: Baceroids, Prevotella, and Ruminococcus

2011- Gosalbes performed the first metatransciptomic analysis of healthy human gut microbiota

2012 - HMP unveils first map of microbes inhabiting healthy humans. Results generated from 80 collaborating scientific institutions found more than 10,000 microbial species occupy the human ecosystem, comprising trillions of cells and making up 1-3% of the bodys mass.

2012 - American Gut Project founded, providing an open-to-the-public platform for citizen scientists seeking to analyze their microbiome and compare it to the microbiomes of others.

2014 - The Integrative Human Microbiome Project (iHMP), begins with goal of studying 3 microbiome-associated conditions.

2016 - The Flemish Gut Flora Project, one of the worlds largest population-wide studies on variations in gut microbiota publishes analysis on more than 1,100 human stool samples.

2018 - The American Gut Project publishes the largest study to date on the microbiome. The results include microbial sequence data from 15,096 samples provided by11,336 participants across the US, UK, Australia and 42 other countries.

What solutions are already (or could be) derived from this dataset?

Biotechnology solutions based off microbiome data have already been developed or are in the process of development. A few key examples are highlighted below:

Probiotics. Probiotics are beneficial bacteria that may prevent or treat certain disease. They were first theorized in 1908 and are now a common food additive. From yogurts to supplements, various probiotics are available for purchase in grocery stores and pharmacies, claiming various benefits. For example probiotic VSL#3 has been shown to reduce liver disease severity and hospitalization in patients with cirrhosis.

Diagnostics. Changes in composition of particular microbes are noted as potential biomarkers. An example includes the ratio of Bifidobacterium to Enterobacteriaceae know as the B/E ratio. A B/E greater than 1 suggests a healthy microbiome and a B/E less than 1 could suggest cirrhosis or particular types of infection.

Fecal Microbiome transplantation (FMT). Although not FDA-approved, fecal microbiome transplantation (FMT) is a widely used method where a fecal preparation from a healthy stool donor is transplanted into the colon of patient via colonoscopy, naso-enteric tube, or capsules. FMT has been used to treat Clostridium difficile infections with 80-90% cure rates (far better efficacy than antibiotics).

Therapeutics. The microbiome dataset is also producing several innovative therapies. Development of bacteria consortia and single strains (both natural and engineered) are in clinical development. Efforts are also underway to identify and isolate microbiome metabolites with important function, such as the methicillin-resistant antibiotics that were identified by primary sequencing of the human gut microbiome.

By continuing to build the microbiome dataset and expand our knowledge of host-microbiome interactions, we may be able correct various states of disease and improve human health.

Disclaimer: The authors above do not necessarily reflect the policies or positions of the organizations with which they are affiliated.

Pam Randhawa, CEO and founder of Empiriko Corporation, Andrew Steinberg, Watson Institute for International and Public Affairs, Brown University, Elizabeth Baca & Elizabeth ODay

For centuries, physicians were limited by the data they were able to obtain via external examination of an individual patient or an autopsy.

More recently, technological advancements have enabled clinicians to identify and monitor internal processes which were previously hidden within living patients.

One of the earliest examples of applied technology occurred in the 1890s when German physicist Wilhelm Rntgen discovered the potential medical applications of X-rays.

Since that time, new technologies have expanded clinical knowledge in imaging, genomics, biomarkers, response to medications, and the microbiome. Collectively, this extended database of high quality, granular information has enhanced the physicians diagnostic capabilities and has translated into improved clinical outcomes.

Todays clinicians increasingly rely on medical imaging and other technology- based diagnostic tools to non-invasively look below the surface to monitor treatment efficacy and screen for pathologic processes, often before clinical symptoms appear.

In addition, the clinicians senses can be extended by electronic data capture systems, IVRS, wearable devices, remote monitoring systems, sensors and iPhone applications. Despite access to this new technology, physicians continue to obtain a patients history in real-time followed by a hands-on assessment of physical findings, an approach which can be limited by communication barriers, time, and the physicians ability to gather or collate data.

One of the largest examples of clinical data collection, integration and analysis occurred in the 1940s with the National Heart Act which created the National Heart Institute and the Framingham Heart Study. The Framingham Original Cohort was started in 1948 with 5,209 men and women between the ages of 30-62 with no history of heart attack or stroke.

Over the next 71 years, the study evolved to gather clinical data for cardiovascular and other medical conditions over several generations. Prior to that time the concepts of preventive medicine and risk factors (a term coined by the Framingham study) were not part of the medical lexicon. The Framingham study enabled physicians to harness observations gathered from individuals physical examination findings, biomarkers, imaging and other physiologic data on a scale which was unparalleled.

The adoption of electronic medical records helped improve data access, but in their earliest iterations only partially addressed the challenges of data compartmentalization and interoperability (silos).

Recent advances in AI applications, EMR data structure and interoperability have enabled clinicians and researchers to improve their clinical decision making. However, accessibility, cost and delays in implementing global interoperability standards have limited data accessibility from disparate systems and have delayed introduction of EMRs in some segments of the medical community.

To this day, limited interoperability, the learning curve and costs associated with implementation are cited as major contributors to physician frustration, burnout and providers retiring early from patient care settings.

However, an interoperability platform known as Fast Healthcare Interoperability Resources (FHIR, pronounced "FIRE") is being developed to exchange electronic health records and unlock silos. The objective of FHIR is to facilitate interoperability between legacy health care systems. The platform facilitates easier access to health data on a variety of devices (e.g., computers, tablets, cell phones), and allows developers to provide medical applications which can be easily integrated into existing systems.

As the capacity to gather information becomes more meaningful, the collection, integration, analysis and format of clinical data submission requires standardization. In the late 1990s, the Clinical Data Interchange Standards Consortium (CDISC) was formed to develop and support global, platform-independent data standards which enable information system interoperability to improve medical research. Over the past several years, CDISC has developed several models to support the organization of clinical trial data.

Milestones in the discovery/development of clinical data and technologies

500BC - The world's first clinical trial recorded in the Book of Daniel in The Bible

1747 - Linds Scurvy trial which contained most characteristics of a controlled trial

1928 - American College of Surgeons sought to improve record standards in clinical settings

Read the rest here:
6 expert essays on the future of biotech - World Economic Forum

KYOTO An expert panel of the health ministry on Friday approved a clinical research program proposed by a Kyoto University team to transplant cartilage made from induced pluripotent stem (iPS) cells to damaged knee joints.

Professor Noriyuki Tsumaki and other members of the team are planning to create cartilage with a diameter of 2 to 3 millimeters using iPS cells stored at the universitys Center for iPS Cell Research and Application (CiRA).

The team aims to carry out the first transplant this year. After a clinical trial by Asahi Kasei Corp., which supports the project, it hopes to put the technology into practical use in 2029.

Four people between the ages of 20 and 70 will undergo transplant operations using iPS cell-derived cartilage for their damaged knee joints, with the area of damage ranging from 1 centimeter to 5 centimeters. The team does not plan to seek additional patients for the program.

The team will monitor the four patients for one year after the operations to keep an eye out for possible development of tumors. If the operations succeed, the transplanted material will fuse with existing cartilage.

There are many patients experiencing inconvenience due to damaged cartilage, Tsumaki told a news conference at the Kyoto University Hospital on Friday. Well work hard so that we can offer therapy methods.

The team will also aim to apply the therapy to patients with osteoarthritis.

In 2014, Riken, a Japanese government-affiliated research institute, transplanted retina cells made from iPS cells as a treatment for an incurable eye disease, in the worlds first transplant of iPS-derived cells.

Later, similar transplant operations were conducted by Kyoto University for Parkinsons disease and by Osaka University for corneal disease.

Excerpt from:
Kyoto University team gets OK from ministry for plan to transplant iPS-derived cartilage into knee joints - The Japan Times

KYOTO A panel of experts from the Ministry of Health approved a clinical research program proposed by a team from the University of Kyoto on Friday for the transplantation of cartilage from induced pluripotent stem cells [iPS] into damaged knee joints.

Professor Noriyuki Tsumaki and other members of the team are planning to produce 2 to 3 millimeter diameter cartilage using iPS cells, which will be stored at the Universitys Center for iPS Cell Research and Application [CiRA].

The team plans to perform the first transplant this year. According to a clinical study by Asahi Kasei Corp., which supports the project, the technology should be put into practice in 2029.

Four people between the ages of 20 and 70 are transplanted with iPS cell cartilage for their damaged knee joints, with the damage range between 1 cm and 5 cm. The team does not plan to seek additional patients for the program.

Immunosuppressors are not used in the transplant because cartilage usually does not show an immune response.

The team will monitor the four patients for possible tumor development for a year after the operation. If the operations are successful, the transplanted material melts into the existing cartilage.

There are many patients who experience discomfort from cartilage damage, said Tsumaki at a press conference at Kyoto University Hospital on Friday. We will work hard to offer therapy methods.

The team will also try to apply the therapy to patients with osteoarthritis.

In 2014, Riken, a research institute affiliated with the Japanese government, transplanted retina cells made from iPS cells to treat an incurable eye disease in the worlds first transplant of iPS-derived cells.

Similar transplants were later performed by Kyoto University for Parkinsons and Osaka University for corneal diseases.

Here is the original post:
The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily

Its not even February yet, and Florida panthers are already having a bad year. Three have been killed by vehicles and one by a train in the first two weeks of 2020 alone.

The big cats once ranged across the South but now are mostly found slinking between fragments of habitat in southern Florida. Traffic poses a significant hazard: Last year 23 panthers were killed by vehicles a significant blow to a wild population that hovers precariously at only around 230 animals.

But there likely wouldnt be any Florida panthers today if it werent for decades of work to save them. The story of how Florida panthers, a puma subspecies, were rescued from the brink of extinction is expertly told in the new book Cat Tale: The Wild, Weird Battle To Save the Florida Panther, by journalist and New York Times best-selling author Craig Pittman. Pittmans been tracking the story for 20 years at the Tampa Bay Times.

The cast of characters and wild turns of event in Pittmans book seem like the stuff of fiction. Theres the Stetson-wearing Texas cougar hunter Roy McBride, who becomes a master panther tracker. Veterinarian Melody Roelke rings the alarm on the panthers genetic problems, only to have her male colleagues look the other way. And the arch villain of the story, a biologist nicknamed Dr. Panther, establishes himself as the preeminent expert but is actually fudging his research and colluding with developers.

Pittman traces these and other characters through years of discoveries, mistakes, public backlash and breakthroughs a fledgling program to radio-collar and track the animals that taught important lessons about tranquilizing big cats high up in trees; a failed captive-breeding program; a failed reintroduction plan in north Florida; and a last-ditch effort to bring in new genes by releasing Texas cougars in panther habitat.

The story is tragic, inspiring and deeply poignant. In his prologue Pittman calls it a scientific cautionary tale. As we grapple with mass extinction across the world, he writes, This is a guide to what extraordinary efforts it takes to bring back just one sub-species one thats particularly popular and what unexpected costs such a decision brings.

Pittman talked to The Revelator about the threats that panthers continue to face and what lessons we can learn about saving other endangered species.

When you first started writing about panthers 20 years ago, what did you think about their prospects?

My first stories were around 1998-1999. Nobody knew if the Texas cougar experiment had worked yet. Things looked pretty grim and a lot of developers were proceeding on the understanding that panthers wouldnt be a problem anymore, so it was OK to build in panther habitat.

Things looked dire at that point and it wasnt until around 2001 or 2002 where you started seeing these new kittens being born and thinking maybe things would be OK. The concern then became making sure that the Texas cougar genetics didnt swamp the panther genetics.

We know that panthers arent out of the woods yet. Is there clear science on what would be considered a recovered population?

Ever since scientists drew up the very first recovery plan decades ago, they said the key was to have three [geographically] separate populations of about 250 or 300 panthers. Obviously, were still a long way from that and from even starting a second population. You could call whats going on in central Florida the start of a new population, but theres just a handful of panthers there.If they choose to follow those particular goals, theyre a long way away.

But I phrase it that way because [the U.S. Fish and Wildlife Service] did not follow their own recommendations when they down-listed manatees [from endangered to threatened]. They didnt follow their recovery plan. They just said, Well, this computer model says its OK, so were going to say its OK, even though the threats are still there.

You know a good bit about manatees, which you wrote about in Manatee Insanity: Inside the War Over Floridas Most Famous Endangered Species. How does the manatees story compare to the panthers?

I call manatees the endangered species you can see, because they will show up everywhere people are theyre in your backyard canal, swimming around your dock. At the time I wrote that book, they were an endangered species, but one that you could see with your own eyes.

Panthers, not so much. Panthers are very elusive. They dont like to be around people. So theyre more of an abstract concept to a lot of folks. People know the panthers exist, but theyve never seen one. So its not quite as personal with panthers.

And the other thing that I wrote about in Manatee Insanity is that the Save the Manatee Club, and specifically its cofounder Jimmy Buffett, came up with this brilliant marketing concept called adopt a manatee, where they took the IDs from a whole bunch of the manatees that the state had been following and, for a contribution of around $5 or so originally, you could adopt a manatee. Youd get a little adoption certificate with the name of your manatee on it and its background.

People became personally invested in the fate of their particular manatee. I was digging through state archives and I saw letters from, you know, Mrs. Johnsons fourth grade class in Mesa, Arizona to the Citrus County Commission saying, Why are you being mean to our manatee and not passing this rule to make boats slow down?

They found a way to make people all over the country care about individual manatees as a way of getting them to care about the species as a whole. Theres no similar project for panthers and generally most of the panthers dont have nicknames like the manatees do.

There are people who absolutely love panthers, mostly in the abstract. And there are some folks who would dearly love to see a hunting season opened on them and feel like the governments lying about how many there are. But I think the majority of Floridians support panthers and are happy that they seem to be coming back.

Your book is a really incredibly in-depth case study of what it takes to save one endangered species. Are there lessons we can learn from it about saving other species?

I like what Melody Roelke said at the point where they started to realize they needed to take action [to save the panthers], it was almost too late to do anything. So her advice was, if you see it heading this way, take action immediately. Dont dawdle around and get into arguments and get mired down in bureaucratic red tape about what youre going to do.

They really were almost too late to save the panther. It basically came down to five female Texas cougars breeding with the remaining male panthers. And had that not worked, that wouldve been it. Theyd probably be gone by now.

The other thing is, if youre going to spend this much money and work this hard to bring back an endangered species, think about whats going to happen afterwards. What are the ramifications going to be? Because as we saw with the captive-breeding experiment that they started and then dropped, they had not planned very well. They had figured out they were going to take these panther kittens out of the wild and breed them in captivity to put [grown] panthers back in the wild, but they hadnt really thought about where they were going to put them and how they were going to train these captive panthers to be OK in the wild.

What are the biggest threats they face now?

The reason I waited so long to write this book is because I needed a good ending and I finally got one. [Editors note: We wont give it away, but its a doozy.]

But just because I found an ending for the book doesnt mean the story of the panther is over. Were now dealing with this mystery ailment thats afflicting some panthers and bobcats, to the point where they cant walk and scientists dont know why.

Weve also got more large development coming down the pike headed for the area [where most panthers live]. In particular theres a proposal backed by the governor who is supposedly pro-environment to build this enormous toll road right through panther habitat, which would bring more development into that area.

One of my colleagues, Lawrence Mower, just wrote a story where wed gotten copies of some emails from Fish and Wildlife Service biologists who study the panthers saying this will just basically be a stake in the heart of panther recovery if you build this toll road through there.

So there are continuing threats, and were a long way from them being considered recovered. But things are looking hopeful in ways they havent for a long time and all because of the very hard work from these folks who labored for years mostly in anonymity because they believed in the cause and they believed that what was going on was something worth devoting their lives to even though it led to burnout and fighting and depression and, in one case, suicide.

In a way, I wrote the book to call attention to the role of those unsung heroes to say, look at what they did, look at the risks that they took, look at the brutal work days they put in trying to figure this out sometimes even against the publics own desires.

Excerpt from:
The Crazy Story of How Florida Panthers Were Saved From Extinction - The Revelator

Companies like Phylos Bioscience are looking to partner with hemp distributors across the nation. Thats why the Portland-based company exhibited at the 2020 Heart of America Agricultural Hemp Classic in Independence, Mo.

Phylos Bioscience is a genetics testing company in the hemp and cannabis space, which identifies male and female plants and also hosts a 3D repository of all the DNA theyve sampled over the years to provide transparency and help farmers to know exactly what they are growing.

Take the time to really do the research on how to grow it, and make sure that whatever variety you do have is actually hemp, said Aaron Jarvis with Phylos.

Jarvis said the company is already working with the Missouri Hemp Association and American Hemp Research, and they intend to develop more partnerships in the days to come.

Listen to Chucks interview with Aaron here: Interview with Aaron Jarvis, Phylos Bioscience

Listen to Aarons presentation here: Presentation by Aaron Jarvis, Phylos Bioscience

2020 Heart of America Agricultural Hemp Classic Photo Album

Original post:
Helping Hemp Farmers to Know What They Grow - AgWired

CRISPR, the breakthrough method for editing genes, has the potential to improve our lives. But one of its inventors warns us scientists may be tempted to change life itself in ways we wont like.

Jennifer Doudna, biochemist who helped invent CRISPR technology. Professor of chemistry, biochemistry and molecular biology at the University of California, Berkeley. (@doudna_lab)

Alta Charo, member of the WHO's advisory committee on developing global standards for governance and over-sight of human genome editing. 2019-2020 Berggruen fellow at theCenter for Advanced Study in Behavioral Sciencesat Stanford University. (@CASBSStanford)

Science Magazine: "Editorial: CRISPR's unwanted anniversary" "There are key moments in the history of every disruptive technology that can make or break its public perception and acceptance. For CRISPR-based genome editing, such a moment occurred 1 year agoan unsettling push into an era that will test how society decides to use this revolutionary technology.

"In November 2018, at the Second International Summit on Human Genome Editing in Hong Kong, scientist He Jiankui announced that he had broken the basic medical mantra of 'do no harm' by using CRISPR-Cas9 to edit the genomes of two human embryos in the hope of protecting the twin girls from HIV.

"His risky and medically unnecessary work stunned the world and defied prior calls by my colleagues and me, and by the U.S. National Academies of Sciences and of Medicine, for an effective moratorium on human germline editing. It was a shocking reminder of the scientific and ethical challenges raised by this powerful technology.

"Once the details of He's work were revealed, it became clear that although human embryo editing is relatively easy to achieve, it is difficult to do well and with responsibility for lifelong health outcomes."

MIT Technology Review: "One of CRISPRs inventors has called for controls on gene-editing technology" "Regulators need to pay more attention to controlling CRISPR, the revolutionary gene-editing tool, says Jennifer Doudna.One year on: Doudna, a University of California biochemist who helped invent CRISPR technology in 2012, wrote an editorial in Science yesterday titled CRISPRs unwanted anniversary.

"The anniversary is that of the announcement by a Chinese scientist, He Jiankui, that he had created gene-edited twin girls. That was a medical felony as far as Doudna is concerned, an unnecessary experiment that violated the doctors rule to avoid causing harm and ignored calls not to proceed.

"A moratorium? Forget about it. So how do we stop this from happening again? Since the 'CRISPR babies' debacle, scientists have talked about self-regulation. One idea was a moratorium: a self-imposed ban of a few years before anyone tries using the technology on the human germline again. (The germline refers to embryos, sperm, and eggsanything that, if you edit it, will cause changes that pass down through the generations.) But that's not going to cut it, says Doudna."

The New York Times: "Jennifer Doudna, a Pioneer Who Helped Simplify Genome Editing" "As a child in Hilo, one of the less touristy parts of Hawaii, Jennifer A. Doudna felt out of place. She had blond hair and blue eyes, and she was taller than the other kids, who were mostly of Polynesian and Asian descent.

'I think to them I looked like a freak,' she recently recalled. 'And I felt like a freak.'Her isolation contributed to a kind of bookishness that propelled her toward science. Her upbringing 'toughened her up,' said her husband, Jamie Cate. 'She can handle a lot of pressure.' These days, that talent is being put to the test.

"Three years ago, Dr. Doudna, a biochemist at the University of California, Berkeley, helped make one of the most monumental discoveries in biology: a relatively easy way to alter any organisms DNA, just as a computer user can edit a word in a document.

"The discovery has turned Dr. Doudna (the first syllable rhymes with loud) into a celebrity of sorts, the recipient of numerous accolades and prizes. The so-called Crispr-Cas9 genome editing technique is already widely used in laboratory studies, and scientists hope it may one day help rewrite flawed genes in people, opening tremendous new possibilities for treating, even curing, diseases."

The New York Times: "Chinese Scientist Who Genetically Edited Babies Gets 3 Years in Prison" "A court in China on Monday sentenced He Jiankui, the researcher who shocked the global scientific community when he claimed that he had created the worlds first genetically edited babies, to three years in prison for carrying out 'illegal medical practices.'

"In a surprise announcement from a trial that was closed to the public, the court in the southern city of Shenzhen found Dr. He guilty of forging approval documents from ethics review boards to recruit couples in which the man had H.I.V. and the woman did not, Xinhua, Chinas official news agency, reported. Dr. He had said he was trying to prevent H.I.V. infections in newborns, but the state media on Monday said he deceived the subjects and the medical authorities alike.

"Dr. He, 35, sent the scientific world into an uproar last year when he announced at a conference in Hong Kong that he had created the worlds first genetically edited babies twin girls. On Monday, Chinas state media said his work had resulted in a third genetically edited baby, who had been previously undisclosed."

Excerpt from:
CRISPR Has The Potential To Improve Lives. But At What Cost? - WBUR

Issued on: 24/01/2020 - 17:12Modified: 24/01/2020 - 17:13

It's called CRISPR-Cas 9 and while the name may not sound impressive, don't be mistaken:this gene-editing technology is set to change our world in many unpredictable ways. We take a closer look in this edition of Tech 24.

It's often referred to as "DNA scissors". CRISPR-Cas 9 is a powerful tool that scientists can use to edit DNA and modify gene functions. It was created byresearchersJennifer Doudnaand Emmanuelle Charpentier in 2012 and it could help eradicate genetically-based diseases like Alzheimer's and HIV.

However, as our reporters Naibe Reynoso and Valrie Defertexplain, this technique isbecoming available to the public even as it's still being tested for safety. Officials in the state of California are worried its use could get out of control.

An important application of genome editing is so-called gene drive, which could help put an end to malaria by altering the genomes of entire mosquito populations.

Our guest Dr. Jacob Corn,Professor of Genome Biology and Principal Investigator at the Corn Lab, ETH Zurichtells us how it could also be the solution to producing more food and doing so more efficiently to feed the world's growing population.

More here:
Tech 24 - CRISPR-Cas9: The era of genome editing - FRANCE 24

New findings using CRISPR have shown that the IL-4 and IL-13 proteins can protect the body against inflammation from autoimmune diseases.

Proteins that play a role in allergies and parasitic infection can also stop the immune system from attacking the body and causing inflamed joints. The researchers suggest their findings will give rise to new drugs for autoimmune diseases such as rheumatoid arthritis.

these proteins prevent neutrophils from migrating into the inflamed join

The investigation, from the Karolinska Institutet, Sweden, revealed that the IL-4 and IL-13 proteins can aid in preventing autoimmune attacks.

These proteins are secreted by immune cells in the presence or allergens or parasitic infections. This then influences the behaviour of neutrophils, a specific type of immune cell. Neutrophils are commonly found in the actively inflamed joints of patients with rheumatoid arthritis and are particularly virulent against tissue as they can secrete non-specific tissue irritants.

Previous research has shown that IL-4 and IL-13 can affect arthritis in experimental models, but exactly how they do so has remained unknown.

The results of this latest study show that these proteins prevent neutrophils from migrating into the inflamed joint. Using CRISPR to modify selected immune-cell genes to understand how they affect cell behaviour, the researchers found that the presence of IL-4 or IL-13 also stimulates an increase in neutrophil surface receptors which have an inhibiting effect on joint inflammation.

We will continue to study these mechanisms and hope that our work can contribute to the development of treatments for rheumatoid arthritis, said principal investigatorDr Fredrik Wermeling, assistant professor at theDepartment of Medicine, Karolinska Institutet.

I have high hopes that the experimental use of CRISPR will be hugely important to our understanding of how immune-cell behaviour is regulated and that this can guide us in the development of new efficacious drugs, concluded Wermeling.

The findings were published in PNAS.

Link:
Researchers use CRISPR to identify proteins that prevent inflammation - Drug Target Review

The CRISPR and CRISPR-Associated (Cas) Genes market research encompasses an exhaustive analysis of the market outlook, framework, and socio-economic impacts. The report covers the accurate investigation of the market size, share, product footprint, revenue, and progress rate. Driven by primary and secondary researches, the CRISPR and CRISPR-Associated (Cas) Genes market study offers reliable and authentic projections regarding the technical jargon.

All the players running in the global CRISPR and CRISPR-Associated (Cas) Genes market are elaborated thoroughly in the CRISPR and CRISPR-Associated (Cas) Genes market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines R&D developments, legal policies, and strategies defining the competitiveness of the CRISPR and CRISPR-Associated (Cas) Genes market players.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1250&source=atm

Trends and Drivers

The products available in the global CRISPR and CRISPR-associated (Cas) genes market are DNA-free Cas and vector-based Cas. The widening applications of these are expected offer several lucrative opportunities to the global market. Out of various applications, genome engineering is expected to be a key contributor to the soaring revenue of the overall market in the near future. This trend will be attributable to eh increasing uptake of genome editing method for the therapeutic development and germline modifications. The report indicates that advancements in plant genome engineering will result in positive impact on the global market.

Analysts predict that CRISPR could be the next biotechnology treatment that has the ability to gradually replace the present single-antibody drugs. Genome engineering is anticipated to pick up a phenomenal pace in the coming years as it is being developed to build an immune response for targeting cancer. The widening application of these methods in the field of oncology is likely to change the game for the global market in the coming years.

Global CRISPR and CRISPR-Associated (Cas) Genes Market: Regional Outlook

In terms of geography, the global market is segmented into North America, Asia Pacific, Latin America, the Middle East and Africa, and Europe. North America is estimated to lead the global CRISPR and CRISPR-associated (Cas) genes market as the U.S. has shown a keen interest in developing effective therapeutics. Asia Pacific is also expected to offer several growth opportunities to the overall market as the region is facing a challenge of mounting unmet medical needs.

Key Players Mentioned in the Report are:

The report has identified the following as the key operating players in the global CRISPR and CRISPR-associated (Cas) genes market: Thermo Fisher Scientific, Inc., Caribou Biosciences, Inc., CRISPR THERAPEUTICS, Addgene, Mirus Bio LLC, Merck KGaA, Editas Medicine, GE Healthcare Dharmacon Inc., Takara Bio USA, Horizon Discovery Group plc, and Intellia Therapeutics, Inc. Analysts predict that these companies will focus on making strategic collaborations to ahead of the competition present in the overall market.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=1250&source=atm

Objectives of the CRISPR and CRISPR-Associated (Cas) Genes Market Study:

The CRISPR and CRISPR-Associated (Cas) Genes market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the CRISPR and CRISPR-Associated (Cas) Genes market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the CRISPR and CRISPR-Associated (Cas) Genes market study provides reliable and authentic projections regarding the technical jargon.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=1250&source=atm

After reading the CRISPR and CRISPR-Associated (Cas) Genes market report, readers can:

Go here to read the rest:
Promising Opportunities in North America and Europe to Propel the Growth of the CRISPR and CRISPR-Associated (Cas) Genes Market 2017 2025 Dagoretti...

The latest version of the 2020 market study on E waste Disposal Market comprising 111 with market data Tables, Charts, Graphs, and Figures which are easy to understand with showcased in-depth analysis.

The global E-waste Disposal market size is estimated at xxx million USD with a CAGR xx% from 2015-2020 and is expected to reach xxx Million USD in 2020 with a CAGR xx% from 2020 to 2025. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of E-waste Disposal by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.

Check out sample report at: https://www.amplemarketreports.com/sample-request/global-e-waste-disposal-market-1316664.html

As per the research and study, the market has settled its presence worldwide. E waste Disposal Market Research study offers a comprehensive evaluation of the Market and comprises a future trend, current growth factors, focused opinions, details, and industry certified market data.

Glancing to 2020, the global market expected to be a significant year for E waste Disposal Market in terms of growth and revenue.

Almost all companies who are listed or profiled are being to upgrade their applications for end-user experience and setting up their permanent base in 2020. This report focused and concentrate on these companies including (Company Profile, Sales Revenue, Price, Gross Margin, Main Products etc.), Sims Recycling Solutions, Eletronic Recyclers International, Kuusakoski, Umicore, Waste Management, Gem, Stena Metall Group, GEEP, Dongjiang, URT, Electrocycling, Cimelia, Veolia, Dynamic Recycling, Enviro-Hub Holdings, E-Parisaraa, environCom, Sage, IRT, Global Electronic Recycling.

Furthermore, the research contributes an in-depth overview of regional level break-up categorized as likely leading growth rate territory, countries with the highest market share in past and current scenario. Some of the geographical break-up incorporated in the study are North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc.), Asia-Pacific (China, India, Japan, Southeast Asia etc.), South America (Brazil, Argentina etc.), Middle East & Africa (Saudi Arabia, South Africa etc.).

With the E waste Disposal market forecast to expand CAGR% in 2020 and with X-X-X-X supposed to be a big beneficiary, it is better positioned than Z-Z-Z-Z for 2020.

According to the AMR market study, Recent trends in consumer preferences market segments such as type, application will be more challenging. E waste Disposal market segment sales will traverse the $$ mark in 2020.

Unlike classified segments successful in the industry such as by Type (Infocomm technology (ICT) equipment, Home appliances) and by End-Users/Application (Material Recycling, Components Recycling).

The 2020 version of the E waste Disposal market study is a further split down / narrowed to highlight the latest emerging twist of the industry.

Enquire more before buy at: https://www.amplemarketreports.com/enquiry-before-buy/global-e-waste-disposal-market-1316664.html

Due to a change in consumer preferences with a review on the latest sales and revenue report submissions, Major vendors in the Global market are trying to get the attention of end-users or consumers by Offerings and additional services.

With using the latest technology and analysis on demand-side, Key players are getting in consumer behavior and their changing preferences.

Again, big investment firms or giants are willing to put more capital to get a key players performance in the market for new applications or products.

Discount, Know more this research report at: https://www.amplemarketreports.com/discount-request/global-e-waste-disposal-market-1316664.html

Research Objectives and Purpose

Read More about this report at: https://www.amplemarketreports.com/report/global-e-waste-disposal-market-1316664.html

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Western / Eastern Europe or Southeast Asia.

With the given market data, Research on Global Markets offers customizations according to specific needs. Write to AMR at [emailprotected], or connect via +1-530-868-6979

About Author

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data. Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Address:

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

https://www.amplemarketreports.com

Read the original post:
CRISPR & CRISPR-associated (Cas) Genes Market Growth Opportunities and Forecast to 2027 - Fusion Science Academy